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ABSTRACT
MCL-1, a well-known pro-survival BCL-2 family member, is indispensable for
the survival of various cellular lineages and is also among the most frequently amplified
genes in a variety of human malignancies. Gene ablation studies previously revealed that
Mcl-1 deficiency leads to embryonic lethality around E3.5 during peri-implantation stage.
Strikingly, the study did not detect any increase in apoptotic cells of the blastocyst,
indicating a function of MCL-1 beyond regulating apoptosis. Our previous studies
revealed an unrecognized role of MCL-1 in promoting mitochondrial physiology, which
is independent of its classical anti-apoptotic function and requires being imported into the
mitochondrial matrix. In order to understand the role of MCL-1 in early embryonic
development, we used CRISPR-Cas9 to target Mcl-1’s start codon on established
embryonic stem cells (ESCs). This approach resulted in the establishment of ESCs in
which MCL-1’s N-terminus was truncated. Biochemical evaluation revealed that Nterminal-deleted MCL-1 retains anti-apoptotic function. However, this truncated MCL-1
is restricted to the mitochondrial outer membrane and functionally these mutated ESCs
showed a dramatic defect in differentiation into the three embryonic germ layersectoderm, mesoderm, and ectoderm. These data suggest that in addition to MCL-1’s
required antagonism of cell death by the C-terminal region, MCL-1’s N-terminus is
required for efficient cellular differentiation, potentially by facilitating MCL-1’s import
into the mitochondrial matrix.
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CHAPTER 1.

INTRODUCTION

The BCL-2 Family and Apoptosis
Apoptosis, or programmed cell death, is important for the proper development
and maintenance of homeostasis throughout the life of all mammals. Dysregulation of
this genetic program leads to human diseases including cancers, autoimmune diseases,
and neurodegenerative disorders [1]. Apoptosis is initiated by cell death stimuli and
converges on the activation of caspases, and cysteinyl aspartate proteases which cleave
protein substrates within the doomed cells to trigger the apoptotic process [2]. Two death
pathways can be distinguished by whether BCL-2 family is required and which caspases
are involved [3] (Figure 1-1).
The extrinsic or death-receptor pathway is triggered by the aggregation of death
receptors (members of the tumor necrosis factor (TNF) receptor family, such as Fas or
TNF receptor-1 (TNFR1)) upon extracellular ligand stimulation. The death receptors
recruit and activate the initiator caspase-8, causing subsequent recruitment of
downstream caspase-3, -6, or -7, without requirement of the BCL-2 family. In certain cell
types, most notably hepatocytes, the extrinsic pathway can intersect the intrinsic pathway
through capsase-8 cleavage-mediated activation by pro-apoptotic BH3-only protein BID
[2] (Figure 1-1).
On the other hand, the intrinsic pathway, or mitochondrial pathway, is strictly
regulated by the BCL-2 family members [3]. The BCL-2 family is composed of antiapoptotic and pro-apoptotic members that share homology with four conserved
amphipathic alpha helical segments named BCL-2 homology domains (BH) numbered
BH1-4 [2]. Anti-apoptotic members (such as BCL-2, BCL-XL, MCL-1, A1 and BCL-w)
possess all four BH domains and form a hydrophobic pocket capable of binding the BH3
domains of other pro-apoptotic members to antagonize apoptosis. The pro-apoptotic
members can be further subdivided according to the number of BH domains they possess;
multidomain pro-apoptotic members (BAX, BAK and BOK) and the divergent subset of
BH3-only members (BAD, BIK, BID, BIM, NOXA, PUMA, etc.) [4-6] (Figure 1-2).
The central dogma for the BCL-2 family in apoptosis is that death signals trigger the
activation of BH3-only proteins which can promote the oligomerization of BAX and
BAK. BAX and BAK oligomers permeabilize the outer mitochondrial membrane (OMM)
and induce the release of several apoptogenic proteins including cytochrome c. Once
cytochrome c is released, it binds to the cytosolic protein apoptotic protease-activating
factor-1 (APAF-1) to facilitate the formation of apoptosome which can recruit and
activate pro-caspase-9. Activated initiator caspase-9 further activates effector caspases
and triggers a cascade of events leading to apoptosis [7] (Figure 1-1).
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Figure 1-1. Scheme depicting intrinsic and extrinsic arms of apoptosis
Apoptosis can be induced by cell surface receptors, such as FAS and tumor necrosis
factor receptor-1 (TNFR1) (extrinsic pathway, right), or by various genotoxic agents,
metabolic insults or transcriptional cues (intrinsic pathway, left). The intrinsic pathway
starts with BH3-only protein induction or post-translational activation, which results in
the inactivation of some BCL-2 family members. This relieves inhibition of BAX and
BAK, which in turn promotes apoptosis. Some BH3-only proteins, such as BIM and
PUMA, may also be able to activate BAX and/or BAK (as shown by the dotted line).
Once activated, BAX and BAK promote cytochrome c release and mitochondrial fission,
which leads to the activation of APAF-1 into an apoptosome and activates caspase-9 to
activate caspase-3. Caspases in turn cleave a series of substrates, activate DNAses and
orchestrate the demolition of the cell. The extrinsic pathway can bypass the
mitochondrial step and activate caspase-8 directly, which leads to caspase-3 activation
and cell demolition. The BCL-2 family regulates the intrinsic pathway and can modulate
the extrinsic pathway when cleavage of BID communicates between the two pathways.
Reprinted with permission from Macmillan Publishers Ltd: Youle RJ, Strasser A. 2008.
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell
Biol 9: 47-59.
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Figure 1-2. The BCL-2 family
The BCL-2 family comprises pro-apoptotic and anti-apoptotic members that share
homology with four conserved amphipathic alpha helical segments named BH1-BH4.
The highly conserved anti-apoptotic family members (BCL-2, BCL-XL, MCL-1 and A1)
contain all four BH domains, of which the BH1-BH3 domains structurally form a pocket
capable of binding the BH3 domains of other family members. Unlike the anti-apoptotic
members, pro-apoptotic members can be subdivided by the number of BH domains they
possess. The more conserved multidomain pro-apoptotic members (BAX, BAK, and
BOK) possess the BH1, BH2 and BH3 domains, which have been also shown to form a
pocket by NMR structural analysis. In contrast, the BH3-only members (BID, BAD,
BIM, BIK, NOXA and PUMA) contain only the BH3 minimal death domain and do not
show sequence conservation outside this domain. Reprinted with permission from
Macmillan Publishers Ltd: Opferman JT, Korsmeyer SJ. 2003. Apoptosis in the
development and maintenance of the immune system. Nature Immunology 4: 410-415.
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Myeloid Cell Leukemia-1
Anti-apoptotic MCL-1 and Cell Survival
MCL-1 is a pro-survival BCL-2 family member that was previously cloned as an
early response gene up-regulated during TPA-induced differentiation of ML-1 human
myeloid leukemia cell line [8]. Sequence comparison of mammalian anti-apoptotic BCL2 family revealed that C-terminus of MCL-1 shares significant homology with BCL-2
and BCL-XL and contains three BH domains (BH2, BH1 and BH3) that form a
hydrophobic cleft to which a BH3 amphipathic alpha-helix of other pro-apoptotic
members can bind [9]. However, MCL-1’s N-terminus is mostly unstructured and
contains signal sequence like characteristics, like PEST sequences (enriched in proline,
glutamic acid, serine, and threonine), accompanied by four pairs of arginines [8]. These
prominent features are also present in various oncoproteins and other proteins which
undergo rapid turnover [8]. Significantly, studies showed that BH domains were not
disrupted by a 151 N-terminal or 23 C-terminal amino acids truncation because the
truncated mutant retains the ability to interact with BIM [10]. Therefore, neither the Nterminus nor C-terminus of MCL-1 is required for its anti-apoptotic function.
MCL-1’s non-redundant and distinct role, compared with other pro-survival BCL2 family members, has been uncovered by gene-ablation methods. Bcl-2 knockout mice
were viable at birth but displayed growth retardation and early postnatal mortality with
severe lymphoid apoptosis, polycystic kidneys, and hypopigmentated hair [11]. Bcl-XL
deficient mice died around embryonic day (E) 13 with dramatic apoptosis of immature
hematopoietic cells and neurons [12]. Bcl-w and A1 knockout mice have also been proved
viable but manifested as spermatogenesis defects and minor defects in hematopoiesis,
respectively [13-15]. Significantly, deletion of Mcl-1 resulted in embryonic lethality due
to peri-implantation failure around E3.5 [16].
Induced deletion of Mcl-1 during early stage of lymphocyte differentiation leads
to dramatically increased apoptosis and arrested the lymphocyte development at pre-Bcell and double-negative T-cell stages. Similar studies also showed MCL-1 is required for
the survival of T cells at multiple stages [17, 18]. In addition, Mcl-1-induced deletion in
early hematopoietic cells results in severe anemia and profoundly reduced bone marrow
cells including hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs),
and common lymphoid progenitors (CLPs) [19] (Figure 1-3). MCL-1 also plays a
selective role during myelopoiesis, supported by the observation that lineage-specific
deletion of Mcl-1 in myeloid precursors resulted in loss of mature neutrophils, but not
macrophages or monocytes [20]. However, although MCL-1 is dispensable for the
survival and differentiation of mature macrophages, it plays a necessary role in regulating
macrophage effector responses during bacterial phagocytosis [21]. Moreover, studies also
identified the absolute requirement for MCL-1 in the sustained survival of NK cells in
vivo under the direct regulation of IL-15 and the survival as well as maintenance of
plasma cells [22, 23]. In contrast, loss of BCL-2 and BCL-XL leads to defects of mature
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Figure 1-3. Role of anti-apoptotic regulators during hematopoiesis
All blood cell lineages arise from a hematopoietic stem cell (HSC) that is capable of selfrenewal and has an indefinite lifespan. HSCs give rise to multipotent progenitors (MPPs)
that retain the ability to give rise to all blood cell lineages, but lack long-term selfrenewal capacity. MPPs can produce two progenitors, common myeloid progenitors
(CMPs) and common lymphoid progenitors (CLPs). CLPs can produce the lymphoid
lineages (B, T, and perhaps NK cells). CMPs produce at least two other oligopotent
progenitor populations, the megakaryocyte erythroid progenitor (MEP) that produce red
blood cells (erythrocytes) and megakaryocytes (generate platelets) and the granulocyte
monocyte progenitor (GMP) that produces granulocytes (neutrophils) and monocytes
(macrophages). Listed beside each differentiation step or progenitor population are the
known anti-apoptotic regulators that promote the survival of the given population. Antiapoptotic MCL-1 has multiple checkpoints, because it has been illustrated to be critical
for the survival of several multipotent and oligopotent progenitor populations (HSC,
CMP, CLP, and GMP) and for the differentiation of granulocytes, but interestingly not
the monocyte lineage. A1-a, a murine ortholog of BFL-1, and other A1 isoforms have
also been shown to play an important role in promoting neutrophil survival in response to
stress but are not absolutely required for development, primarily effecting mature cell
survival (indicated by open arrowhead). A1 isoforms also play a role, but are not essential
in lymphoid development. In the erythroid lineage, it appears that anti-apoptotic BCL-XL
is the essential survival molecule, but unpublished data indicate that MCL-1 may also
play an essential role during early differentiation. In the megakaryocytic lineage, it
appears that, although neither MCL-1 nor BCL-XL is solely responsible for survival, the
two pro-survival molecules appear to have overlapping functions (indicated by open
arrowheads) in promoting megakaryocyte survival. Reprinted with permission from
Elsevier Ltd: Perciavalle RM, Opferman JT. 2013. Delving deeper: MCL-1’s
contributions to normal and cancer biology. Trends in Cell Biology 23: 22-29.
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lymphocytes and red blood cells, respectively [11, 24]. A1 isoforms play a role, but are
not indispensable in granulocyte and lymphoid development [14, 25]. These studies
indicate MCL-1 is essential for the survival and differentiation of multiple hematopoietic
lineages while the other pro-survival members play much more selective roles in
hematopoiesis (Figure 1-3).
In addition to its essential role at different stages of hematopoiesis, MCL-1 is an
important pro-survival factor in the hearts supported by the evidences that cardiacspecific ablation of Mcl-1 resulted in a rapidly fatal, dilated cardiomyopathy by a loss of
cardiac contractility, abnormal mitochondria ultrastructure, and defective mitochondrial
respiration [26, 27]. MCL-1 is also a required molecule for cortical neurogenesis and the
survival of neurons under DNA damage. Induced deletion of Mcl-1 resulted in
widespread cell death of neuronal progenitors and predisposed neurons to acute DNA
damage [28]. Moreover, MCL-1 has been reported to be expressed in many normal
human tissues, such as various epithelial tissues, neuroendocrine cells, sympathetic
neurons, pancreatic islets cells, Leydig cells of the testis, cardiac muscles, skeletal
muscles, chondrocytes, and hepatocytes [29, 30]. The function of MCL-1 in many of
those human tissues still remains to be established.
MCL-1 is also one of the most frequently amplified genes in a variety of human
cancers, such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia
(AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML),
neuroblastoma, melanoma, breast, lung cancer, etc. [31]. More importantly, elevated
level of MCL-1 expression often correlates with disease progression, chemotherapeutic
resistance and relapse [32-35]. The rationale for cancer cells displaying high level of
MCL-1 is that they often violate important cellular checkpoints which can drive the cells
to die through apoptosis. Thus, cancer cells need certain strategies for survival under the
apoptotic stress by either downregulating pro-apoptotic regulators or, more frequently,
upregulating pro-survival members like MCL-1 [36]. Kotschy et al. developed a small
molecule S63845 that specifically binds to the BH3-binding groove of MCL-1 with high
affinity and showed its potent anti-tumor activity with an acceptable safety margin either
alone or in combination with other anti-cancer drugs in treating a wide range of tumors,
including multiple myeloma, leukemia, lymphoma cells and various solid tumors [37].
Non-canonical Function of MCL-1
Sub-mitochondrial Localization of MCL-1. MCL-1 protein usually appears as
a doublet (40 kD and 36 kD) or even triplet (40 kD, 38 kD and 36 kD) on immunoblots of
many cell types. Several approaches have been adopted to decipher the banding pattern
[38]. Phosphorylation of MCL-1 has been proposed to give rise to the 40 kD isoform,
however, phosphatase treatment does not abolish the 40 kD species. It has been suggested
that non-canonical translational initiation produces the faster-migrating 36 kD protein,
however, mutation of the start codon of MCL-1 only generates a 30 kD truncated protein
from a downstream ATG codon. Furthermore, ablation of the putative splice donor and
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acceptor still gives rise to the same banding pattern indicating that a non-canonical
messenger RNA splicing is not the reason [38]. Therefore, proteolytic cleavage is the
most likely contributor to the pattern. Indeed, Edman sequencing reveals two cleavage
sites, one between isoleucine 10 and glycine 11 and another between leucine 33 and
valine 34. Consequently, proteolytic cleavage of the N terminus of MCL-1 generates
three different MCL-1 species: full-length 40 kD, middle band 38 kD cleaved at
isoleucine 10 and lower band 36 kD cleaved at leucine 33 [38].
Unexpectedly, further experiments exhibited different mitochondrial sublocalization; the upper and middle forms of MCL-1 (40 kD and 38 kD) reside in the outer
mitochondrial membrane (OMM) as both species are sensitive to proteinase K digestion
performed on the isolated mitochondria, whereas the lower form (36 kD) appears to be
confined within the mitochondrial matrix as it is completely resistant to enzyme
digestion. Moreover, the importation of MCL-1 into the mitochondria is mediated by the
translocases of outer membrane (TOM) and inner membrane (TIM) supported by the
evidence that RNA-mediated interference (RNAi) gene silencing of either TOM40 or
TIM50 abrogates its import, rendering it completely proteinase K sensitive [38]. A
similar study also showed that the fast-mobility (FM) isoform of MCL-1 is localized to
the mitochondrial matrix and that a mitochondrial processing peptidase (MPP) is
responsible for the N-terminal processing of MCL-1 to generate the FM species. The Nterminal 33 amino acids of mouse MCL-1 serve both as mitochondrial targeting and
processing signal [39].
MCL-1 Possesses Multiple Functions in Mitochondria. Perciavalle et al.
further have successfully made mutants to dissect MCL-1’s two isoforms and shown that
two species of MCL-1 retain different functions due to distinct subcellular localization.
The OMM localized MCL-1 performs the classical anti-apoptotic function by
antagonizing BAX and BAK. However, the matrix localized MCL-1 does not possess
anti-apoptotic activity, but plays a role in maintaining mitochondrial ultrastructure,
promoting mitochondrial fusion and fission, supporting the assembly of ATP synthase
oligomers and oxidative phosphorylation. As supported by the SV40-transformed Mcl1flox/flox Rosa-ERCreT2 MEFs, when deletion of Mcl-1 is induced by tamoxifen, it results
in abnormal mitochondrial cristae structure, delayed mitochondrial fusion and fission,
decreased ATP levels, mitochondrial membrane potential, oxygen consumption rates
(OCRs), mitochondrial DNA contents, increased reactive oxygen species (ROS), and
defected electron transport chain (ETC) supercomplexes and ATP synthase
oligomerization. These phenotypes could be only rescued by full-length or matrix
localized species of MCL-1 but not by the OMM localized isoform [38]. Therefore, other
than its classical anti-apoptotic function, MCL-1 performs multiple functions in
mitochondria in promoting mitochondrial physiology and supporting mitochondrial
ultrastructure [40] (Figure 1-4). However, whether MCL-1 functions directly or
indirectly to facilitate mitochondrial physiology still requires further investigation.
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Figure 1-4. Model for MCL-1’s potential functions in mitochondria
MCL-1 possesses multiple functions in mitochondria. (a) On the outer mitochondrial
membrane (OMM), MCL-1 functions like other anti-apoptotic BCL-2 family members
where it acts to prevent the activation of BAX and BAK to prevent cell death. MCL-1
can directly bind BH3-only family members, such as BIM, sequestering them away from
the pro-apoptotic effectors BAX and BAK. Alternatively, MCL-1 may directly bind BAX
and BAK and maintain them in an inactive conformation. (b) During mitochondrial
importation, the full-length MCL-1 is proteolytically truncated at its amino terminus. The
truncated, matrix-localized MCL-1 resides within the inner mitochondrial membrane
(IMM), where it functions to maintain mitochondrial cristae ultrastructure and promotes
the assembly of the electron transport chain (ETC) complexes into higher-order
assemblies known as supercomplexes. The assembly into supercomplexes has been
shown to facilitate electron transport efficiency and reduce the production of deleterious
reactive oxygen species. Additionally, matrix-localized MCL-1 facilitates the higher
order assembly of the ATP synthase complexes into dimers and oligomers. Proper
assembly of oligomeric ATP synthase has been implicated as being an important
determinant of inner membrane cristae structure. Genetic ablation of Mcl-1 results in
defects in both supercompexes and ATP synthase oligomer assembly. Whether MCL-1
acts directly or indirectly to facilitate these macromolecular assemblies of the electron
transport supercomplexes or ATP synthase oligomers remains unclear. Reprinted with
permission from Elsevier Ltd: Perciavalle RM, Opferman JT. 2013. Delving deeper:
MCL-1’s contributions to normal and cancer biology. Trends in cell biology 23: 22-29.
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Mitochondria in Human Development and Diseases
Mitochondria are cytosolic double-membrane bound organelles found in almost
all eukaryotic organisms and are known to be essential for cellular life and death
regulation. They play a critical role in the life of the cell by carrying out energy-yielding
oxidative reactions and electron transport chain activities which provide vast majority of
ATP necessary for all cellular functions. Interruption of this mitochondrial function in
vivo results in death, as dramatically presented by the mitochondrial electron transport
chain (ETC) poisons as cyanide [41]. The proteins involved in oxidative phosphorylation
(OXPHOS) and ETC components reside within the mitochondrial inner membrane. The
ETC utilizes hydrogens generated through either the tricarboxylic acid (TCA) cycle from
carbohydrates or the fatty acid β-oxidation from fats and atomic oxygen to make ATP
and water [42, 43] (Figure 1-5). Moreover, OXPHOS also generates the major
endogenous source of reactive oxygen species (ROS) as byproducts. Mitochondrial ROS
are essential signaling pathway molecules as well as potent mitogens, however, too much
ROS is toxic to the cells and can result in cellular death. Mitochondrial ROS production
and redox balance are modulated by the mitochondrial inner membrane electrochemical
gradient [42, 43] (Figure 1-5).
Mitochondria and Human Development
Mitochondria are dynamic organelles, the shape, size and number of which are
highly variable and are controlled by fusion and fission [44]. The core mitochondrial
fusion machinery in mammals consists of two related proteins mitofusins MFN1 and
MFN2, which are essential for adjacent mitochondria during the fusion process [45-49].
Optic atrophy protein 1 (OPA-1), a mitochondrial dynamin-related protein, is another
required molecule for fusion of the mitochondrial inner membranes, a function that
consistent with its intermembrane space localization and inner membrane association [50,
51]. Mitochondrial fission is dependent on the recruitment of a dynamin-related protein 1
(DRP1) in mammals from the cytosol. DRP1 has been proposed to assemble into rings
and spirals that encircle and constrict the mitochondrial tubule during fission [52].
Mitochondrial dynamics has been well known for several important biological
functions. First, the balance between fusion and fission controls the shape, length, and
number of mitochondria, which is highly dependent on the cell type and cellular energy
status [53]. Second, fusion and fission processes allow mitochondria to exchange lipid
membranes, mtDNAs and other intra-mitochondrial content, which helps maintain a
healthy mitochondrial population [49, 54, 55]. Third, the dynamic characteristics of
mitochondria help to distribute the mitochondria to specific subcellular compartment,
which is extremely important in highly polarized cells, like neurons [56-58]. Due to these
essential cellular functions, mitochondria are required for various biological processes,
especially human development, and perturbations result in specific developmental
defects.
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Figure 1-5. Mitochondrial physiology
Mitochondria lie at the nexus of most biosynthetic pathways, produce much of the
cellular energy through oxidative phosphorylation (OXPHOS), regulate mitochondrial
and cellular redox status, generate most of the reactive oxygen species (ROS), regulate
Ca2+ concentrations and can initiate apoptosis by the activation of the mitochondrial
permeability transition pore (mtPTP). The mtPTP can be activated by a decreased
membrane potential, high-energy phosphates (such as ADP), a more-oxidized redox
status, and/or increased mitochondrial matrix Ca2+ and ROS concentrations. Reducing
equivalents and acetyl-CoA enter the mitochondrion via pyruvate and fatty acids.
Pyruvate is transported through the mitochondrial inner membrane by the pyruvate
transporter (PT), binds to pyruvate dehydrogenase (PDH), which may be membraneassociated, and is oxidatively decarboxylated to produce acetyl-CoA. Inhibition of
mitochondrial function results in pyruvate accumulation in the cytosol, where it can be
reduced to lactate. Fatty acids are imported into the mitochondrion bound to carnitine. In
the cytosol, fatty acids bound to CoA are transferred to carnitine, transported through the
outer and inner mitochondrial membranes, and then transferred back to CoA for βoxidation. The transfer of fatty acyl groups between CoA and carnitine is mediated by the
carnitine palmitoyltransferases (not shown). As a by-product of OXPHOS — the
substrates and products of which are transported through the outer membrane by the
voltage-dependent anion channels (VDACs) — mitochondria generate ROS by the
donation of excess electrons from complexes I and III directly to O2 to generate
superoxide anions (O2•−). Matrix O2•−, primarily from complex I, is dismutated to H2O2
by the mitochondrial matrix Mn superoxide dismutase (MnSOD; also known as SOD2),
while intermembrane-space O2•−, which is primarily from complex III, is dismutated by
Cu/Zn superoxide dismutase (Cu/ZnSOD; also known as SOD1). H2O2 can be reduced to
water by glutathione peroxidase using reduced glutathione as an electrondonor. Oxidized
glutathione is reduced by glutathione reductase using NADPH as a reductant. In the
presence of reduced transition metals, H2O2 can be reduced to hydroxyl radicals (•OH),
which are the most reactive ROS. The mtPTP is a protein complex that is thought to
include the translocator protein (TSPO; also known as PBR), an unknown innermembrane channel, adenine nucleotide translocators (ANTs) and the cyclosporine-Asensitive cyclophilin D (CYPD; also known as PPID), which are regulatory, in
association with the BCL-2 pro- and anti-apoptotic family members. When activated, the
mtPTP forms a channel between the inner and outer membranes, which short-circuits ΔP.
This is associated with the aggregation of BAX and BAD in the mitochondrial outer
membrane to form a megachannel. The megachannel releases pro-apoptotic proteins from
the intermembrane space into the cytosol to initiate the degradation of the cellular
proteins and DNA. AIF, apoptosis-inducing factor; CoA-SH, coenzyme A with a free
sulphydryl group; CoQ, coenzyme Q10; ENDOG, mitochondrial endonuclease G; GPX,
glutathione peroxidase; LDH, lactate dehydrogenase; OAA, oxaloacetate; SMAC, second
mitochondria-derived activator of caspase; TCA, tricarboxylic acid. Reprinted with
permission from Macmillan Publishers Ltd: Wallace DC. 2012. Mitochondria and cancer.
Nature Reviews Cancer 12: 685-698.
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Previous studies revealed that mice deficient in either MFN1, MFN2 or OPA-1
die in midgestation [54, 59-61]. They further showed that MFN2 lacking embryos have a
severe and specific disruption of the placental trophoblast giant cell layer. However,
MFN1-deficient giant cell layers are normal but MFN1 deficient mice still die due to
placental defects [54, 62]. A case of a newborn girl bearing a dominant-negative
dynamin-related protein 1 (DRP1) allele has been reported. The patient died around 1
month old and had a wide range of defects, such as microcephaly, abnormal brain
development, optic atrophy and hypoplasia, persistent lactic academia, and elevated
serum very-long-chain fatty acid [63].
Human reproduction, from oogenesis, fertilization to peri-implantation embryo
development, has been suggested to be highly associated with the rate of mitochondrial
replication as well as their activities. The optimal rate of oxygen consumption and fine
regulation of aerobic and anaerobic respiration pathways are required for proper
development [64].
Mitochondria and Human Diseases
Mitochondria are more than just a powerhouse of the cell. They have been
reported to be intensively involved in the regulation of metabolism, cell-cycle control,
development, antiviral responses and cell death (discussed earlier) [65]. Mitochondrion
distinguishes itself from other organelles because it has its own mitochondrial DNA
(mtDNA). The modern mammalian mtDNA has 13 polypeptide genes which encode
essential components of OXPHOS. It also encodes the 12S and 16S rRNA genes and the
22 tRNA genes required for mitochondrial protein synthesis [66]. Nuclear genes encode
the remaining mitochondrial OXPHOS proteins, the metabolic enzymes, the DNA and
RNA polymerases, the ribosomal components and the mtDNA regulatory factors [42].
Mutations on either mtDNA or mitochondrial function associated nuclear genes have
been reported to be related to human diseases [42].
Human Diseases Associated with MtDNA Mutations. Mutations from either
base substitutions or rearrangements of mtDNA causes human diseases. A missense
mutation from a G to A transition in mitochondrial ND6 gene, which encodes a subunit of
NADH dehydrogenase, has been associated with Leber’s hereditary optic neuropathy
(LHON) [67]. Patients with LHON present with sudden-onset blindness in their early
twenties because of the death of the optic nerve [67, 68]. Rearrangement mutations of
mtDNA lead to diseases including chronic progressive external ophthalmoplegia (CPEO),
Kearns-Sayre Syndrome (KSS), diabetes mellitus inherited from maternal side and
deafness [69-72]. CPEO and KSS patients, for example, present with similar
mitochondrial myopathy including ophthalmoplegia, ptosis and a subset of cardiac, renal,
endocrine problems.
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Human Diseases from Mutations in Mitochondrial Function Related Nuclear
Genes. Mitochondrial diseases resulting from mutations in mitochondrial functions
related nuclear genes share many of the clinical characteristics of mtDNA mutations. For
instance, a mutation of the gene encoding one structural protein of electron transport
chain (ETC) complex I has been reported in a young patient presenting hypotonia, mental
retardation, seizure episodes, and basal ganglia degeneration [73]. Friedreich’s ataxia, an
autosomal recessive disease, is an example that mutations in nuclear genes can affect
OXPHOS or destabilize mtDNA indirectly. The encoded protein, frataxin, is imported to
the mitochondrial inner membrane and performs function to transport iron out of the
mitochondrion. When mutated, iron accumulates in the mitochondrial matrix, stimulating
the overproduction of oxidative stresses. Patients present with cerebellar ataxia,
peripheral neuropathy, and hypertrophic cardiomyopathy [74].
Mitochondria and Cancer
Functional mitochondria are essential for cancer cell survival. Contrary to
conventional opinions, although mutations affecting mitochondrial functions are common
in cancer cells, they do not inactivate the energy and metabolic reactions but rather
reprogram the mitochondrial bioenergetics and biosynthetic status to meet the
requirements of the cancer cells [43]. And cancer therapies targeting mitochondria have
been shown to be promising for cancer treatment [75].
MtDNA Mutations and Cancer. Although functional mitochondria are essential
for cancer cell survival, mtDNA mutations and/or reduced mtDNA copy numbers are
common features of cancer cells, which suggests that altered mitochondrial bioenergetics
and/or metabolism play an important role in tumor transformation and maintenance [43].
For example, the missense mutation of MTND3 gene, encodes ETC complex I subunit,
has been reported to be linked with increased risk for breast cancer in African American
women [76]. And another missense mutation of cytochrome c oxidase subunit 1
(MTCO1) T6777C has been associated with epithelial ovarian cancer, along with several
nuclear DNA mitochondrial genes variants [77]. A meta-analysis has revealed that many
cancer-associated mtDNA mutations consistently and obviously inhibit OXPHOS, which
might serve to either stimulate tumor transformation or promote cancer cell adaptation to
the tumor environment [43].
Mitochondrial Signaling Pathway and Cancer. Several hallmark cancer
signaling pathways have been reported to reprogram mitochondrial physiology in order to
promote tumor cell transformation, including c-MYC, K-RAS, PI3K and TP53 signaling
pathways. For example, in addition to the various effects of oncogenic K-RAS signaling
on proliferation, apoptosis and metabolism, it has also been reported to downregulate
mitochondrial respiration and promote mitochondrial fission to support malignant
transformation [78]. Another classical example should be PI3K-AKT-mTOR signaling
pathway which has been shown to be overactive in many human cancers. The pathway in
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cancer cells is often overstimulated by either oncogenic mutations in signaling kinases or
loss-of-function mutations of tumor suppressor proteins like PTEN, which then activates
the downstream effector mechanistic target of rapamycin (mTOR). mTOR, a core
component of two distinct protein complexes mTORC1 and mTORC2, functions as a
serine/ threonine protein kinase that regulates many biological activities, such as cell
growth, proliferation, cell survival, protein synthesis, autophagy, and transcription [79].
PI3K-AKT-mTOR signaling pathway also inhibits carnitine palmitoyltransferase IA
which is the rate limiting step for fatty acid oxidation and phosphorylates hexokinase II
which is known to capture mitochondrial ATP and utilize it to convert glucose to
glucose-6-phosphate. All these effects from activation of PI3K-AKT-mTOR pathway
help the shift from oxidative phosphorylation to more glycolytic metabolism, which is
more favorable for cancer cell transformation and proliferation [43].
Oxidative Stress and Cancer. Reactive oxygen species (ROS), in the form of
superoxide (O2.-), hydroxyl free radicals (OH.), and hydrogen peroxide (H2O2), are
produced from multiple physiological reactions, including electron transport through the
ETC complex 1 and NAD(P)H oxidases. Mitochondria not only are the major
contributors to cellular ROS production but also have multiple antioxidant strategies to
neutralize ROS, such as superoxide dismutase (SOD2), glutathione, thioredoxin, and
peroxiredoxins [78]. There are two faces of ROS biology: redox signaling and oxidative
stress [80]. While redox signaling is essential for various cellular processes, such as
proper cellular differentiation, proliferation, and tissue regeneration, high levels of ROS
leads to oxidative stress which incur damage to DNA, protein or lipids, resulting in
genomic instability to promote cancer cell transformation [80].
Well-known tumor suppressor p53 controls the expression of many antioxidant
genes and it is been shown that tumor initiation in Trp53-/- mouse models can be
successfully inhibited by antioxidant NAC supplementation in the diet, indicating a tumor
suppressive function of p53 through regulating antioxidant and metabolism genes rather
than apoptosis and cell cycle arrest [81-83]. Another example is that H2O2 has been
suggested to inactivate tumor suppressor PTEN by oxidizing its cysteine residues and
promoting the formation of a disulfide bond, which prevents PTEN from inhibiting PI3K
pathway [84]. ROS-mediated regulation of oncogenic signaling has also been revealed to
affect metastasis. As reported by Porporato et al. oxidation of cysteines in SRC increases
its oncogenicity, facilitating tumor cell migration and metastasis in multiple tumor types,
which can be blocked by a ROS scavenger [85].
While ROS play an essential role in activating proper mitogenic signals to
promote cancer cell proliferation, survival and metabolic adaptation, too much ROS
make cancer cells susceptible to oxidative stress-induced cell death. Therefore, cancer
cells have to maintain ROS levels in a window which can stimulate proliferation without
causing cytotoxicity [80]. The dependence on upregulated antioxidant pathways may act
as an Achilles heel for cancer therapies. Combined therapy of glutathione and thioredoxin
inhibitors has been shown to limit tumor growth in breast cancer models both in vitro and
in vivo [78].
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Targeting Mitochondria for Cancer Therapy. Cancer cells adopt an extensive
metabolic reprogramming, which makes their mitochondria structurally and functionally
different from their normal counterparts and renders them more susceptible to the
mitochondrial targeted therapies [75]. Several selective mitochondria targeted strategies
have already been shown to be promising on a variety of cancer models. Targeting
mitochondrial permeability transition pore complex (MPTP) is one of the examples [8691]. Multiple compounds have been developed to act on the components of the MPTP to
induce the outer mitochondrial membrane permeabilization and apoptosis. Another
strategy is to design compounds that induce the overproduction of ROS or inhibit
antioxidant systems. Motexafin gadolinium has been suggested to selectively accumulate
in many types of cancers, exhibiting an overproduction of ROS and enhancing the in vivo
response to radiotherapy on lung cancer as well as pediatric glioblastoma [92, 93]. There
are now sufficient evidences suggesting shifting the balance of the ratio between proapoptotic versus anti-apoptotic BCL-2 proteins primes cancer cells to die through
MOMP-dependent apoptosis. One of the most well-recognized and best established
example is BH3 mimetics, ABT-737, which specifically binds to BCL-2, BCL-XL and
BCL-W and induces tumor cell death [94-97]. Last but not least, approaches reversing the
hyperglycolytic state of cancer cells also have been shown to be successful in clinical
trials. 2-deoxy-D-glucose (2DG), an inhibitor of glycolysis, has been revealed to
significantly synergize with cisplatin on the cytotoxicity in treating human head and neck
cancer cells [97].
CRISPR-Cas9 System for Genomic Editing
In recent years, the development of genome engineering technologies, the process
of making targeted genome modification in their endogenous context, allow researchers
to rapidly and efficiently recapitulate biological functions or disease phenotypes of
genetic mutations or epigenetic variants in cellular or animal models. It enables the direct
correction of genetic or epigenetic defects in somatic tissues for genetically encoded
disorders [98]. Generally speaking, directed genomic modification is achieved by
targeting a genome-editing nuclease to the specific sequences in the genome, which
recognize and cut at the specific site to generate double-strand breaks (DSBs). Generated
DSBs can be further repaired by one of the two cellular endogenous DNA repair
mechanisms: non-homologous end joining (NHEJ) or homology-directed repair (HDR)
when a repair donor template DNA provided. NHEJ is highly efficient however errorprone, which results in small insertions or deletions (indels) at the targeted locus and
therefore leads to shift reading frame to generate nonfunctional proteins. By contrast,
HDR-based gene repair can be used to create knockin sequences at targeted site when a
donor template DNA containing homologous arms is delivered [99].
There are four major strategies that are currently performed to introduce DSBs in
the genome: meganucleases, zinc-finger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENs), and the clustered regularly interspaced short palindromic
repeat (CRISPR)-Cas system [100-103]. Meganucleases target various sequences and
they are considered as the most specific strategy due to the recognition sequences are
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long enough to occur only with a very low chance. However, the requirement that DNA
recognition and cleavage sites need to be linked closely limits the broad application of
those nucleases [101]. ZFNs are generated via the fusion of a zinc-finger DNA binding
domain with the cleavage domain called FokI nuclease that acts as a dimer [102].
TALENs are composed of the DNA binding domain called transcription activator-like
effector (TALE) and a FokI nuclease [103]. All three, meganucleases, ZFNs, and
TALENs, create DNA targeted sequence recognition specificity via protein-DNA
interaction and require labor- or time-consuming protein engineering or assembly [99].
RNA-guided endonuclease Cas9 from the microbial adaptive immune system
CRISPR has been developed in the recent 5 years and provides a highly sensitive and
precise system for achieving targeted mutagenesis in eukaryotic cells with its ease of
customization and high efficiency. The Cas9 nuclease is paired and targeted to genomic
DNA by a guide RNA consisting of a 20-nucleotide sequence and a scaffold with the
guide sequence required to be directly upstream of a 5’-NGG adjacent motif called PAM
motif [104] (Figure 1-6). Then, Cas9 endonuclease induces a double strand break around
3 bp upstream of the PAM motif. DSBs can be repaired by either NHEJ pathway, which
results in random indels to make a gene knockout, or homologous recombination, which
allows for high fidelity and precise editing when a repair template is provided [104]
(Figure 1-7).
CRISPR-Cas9 system has enabled efficient and accelerated generation of
transgenic models to allow for recapitulating genetic mutations found in patient
populations, which facilitates the study of disease mechanisms and therapeutic targets
[98, 105]. Researchers have also applied this technology to engineer isogenic ES or iPS
from patients with specific mutations and then induce those stem cells to differentiate and
recapitulate the disease development models and screen for therapeutic targets [106].
Genome-wide loss-of-function screening can be performed by mass synthesis and
delivery of guide RNA libraries to disrupt thousands of genomic elements in parallel to
study candidate genes affecting phenotypes [107, 108]. In addition to a research tool that
has been widely used, CRISPR-Cas9 system is also a potential strategy for therapeutic
purpose. For example, some monogenic diseases such as cystic fibrosis, sickle-cell
anemia, etc. have loss-of-function mutations due to small deletions or replacements that
can be corrected by Cas9-induced gene repair [98, 106]. Other than repairing underlying
mutations, Cas9-mediated NHEJ repair can be utilized for introducing protective
mutations, such as Cas-9-induced inactivation of the CCR5 receptor, a co-receptor
required for HIV incorporation [109]. Despite many of the advantages, challenges need to
be addressed, such as finding the efficient delivery systems, reducing the off-target
effects, and monitoring the long-term safety issues [98].
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Figure 1-6. Schematic of the RNA-guided Cas9 nuclease
The Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown for
example is the human EMX1 locus) by a sgRNA consisting of a 20-nt guide sequence
(blue) and a scaffold (red). The guide sequence pairs with the DNA target (blue bar on
top strand), directly upstream of a requisite 5’-NGG adjacent motif (PAM; pink). Cas9
mediates a DSB around 3 bp upstream of the PAM (red triangle). Reprinted with
permission from Macmillan Publishers Ltd: Ran FA, Zhang F. 2013. Genome
engineering using the CRISPR-Cas9 system. Nature Protocol 8: 2281-2308.

Figure 1-7. DSB repair promotes gene editing
DSBs induced by Cas9 (yellow) can be repaired in one of two ways: In the error-prone
NHEJ pathway, the ends of a DSB are processed by endogenous DNA repair machinery
and rejoined, which can result in random indel mutations at the site of junction. Indel
mutations occurring within the coding region of a gene can result in frameshifts and the
creation of a premature stop codon, resulting in gene knockout. Alternatively, a repair
template in the form of a plasmid or single-stranded DNA oligonucleotides (ssODN) can
be supplied to leverage the HDR pathway, which allows high fidelity and precise editing.
Single-strand nicks to the DNA can also induce HDR. Reprinted with permission from
Macmillan Publishers Ltd: Ran FA, Zhang F. 2013. Genome engineering using the
CRISPR-Cas9 system. Nature Protocol 8: 2281-2308.
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CHAPTER 2.

MATERIALS AND EXPERIMENTAL PROCEDURES
Mice

Mcl-1flox/flox CreERT2, Mcl-1flox/WT CreERT2 and Mcl-1flox/flox ESCs were generated at
E3.5 from the C57BL/6 mice with respective genotypes. CreERT2 is a tamoxifen inducible
Cre recombinase system. To induce deletion, five doses of tamoxifen emulsified in
sunflower oil vehicle (Sigma) were performed through gavage (1 mg per dose; Sigma).
All conditional mice were on a C57BL/6 background and littermates were used as
controls. Nu/J mice used for teratoma formation assays were obtained from Jackson
Laboratory. C57BL/6J mice (Jackson Laboratory) were used for zygote injections. All
mice were maintained in accordance with the Institutional Animal Care and Use
Committee of St. Jude Children’s Research Hospital as required by the U.S. Animal
Welfare Act and National Institutes of Health Policy for proper care and use of laboratory
animals for research.
Cells and Cell Culture
The 129/SvJ ES cell line F12, derived by Jacqueline Surtel (St. Jude Children’s
Research Hospital) was routinely cultured on tissue-culture treated dishes (Corning) in
ESCs medium, consisting of 90% glucose-free Dulbecco’s modified Eagle’s medium
(DMEM, Lonza), 10% fetal bovine serum (FBS, Hyclone), 100 U/ml penicillin, 100
ug/ml streptomycin, 2 mM L-glutamine (all from Invitrogen), 0.1 mM mercaptoethanol
(Gibco), and 103 U/ml recombinant mouse leukemia inhibitory factor (LIF from
Millipore). Mcl-1-conditional ESCs were derived at E3.5 from Mcl-1-conditional mice
breedings described previously. Once plugs were observed at E0.5, mice uteri were
dissected under the microscope and blastocysts were flushed. Inner cell masses (ICMs)
were separated from the whole blastocysts and transferred onto pre-coated irradiated
MEFs. After expansion, single cell clones were picked for genotyping. Mcl-1 conditional
ESCs were grown in the same medium as F12 ESCs.
SV40-transformed Mcl-1 conditional mouse embryonic fibroblasts (MEFs) have
been previously described [17]. To induce Mcl-1 deletion, the MEFs were treated for 48
hours with 100nM 4-hydroxy-tamoxifen (Sigma) in culture medium. HEK 293T cells
were obtained from American Type Culture Collection. Arfnull GFP MEFs, derived by Dr.
Frederique Zindy (St. Jude Children’s Research Hospital), were exposed to 4000 rads
from a γ-radiation source and used as stromal cells. All MEFs, HEK 293T cells and
irradiated MEFs were grown in 90% glucose-free DMEM (Invitrogen) supplemented
with 10% FBS (Gibco), 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine
(all from Invitrogen), and 0.1 mM mercaptoethanol (Gibco).
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Plasmids, Expression Constructs, and Generation of Mutants
All Mcl-1 constructs were generated according to mouse Mcl-1 cDNA. The
mutants Mcl-1 cleavage site (CS) 10, 11 and Mcl-1 CS 33, 34, in which isoleucine, lysine
and leucine, valine were replaced by aspartic acid, were derived by site-directed
mutagenesis (Stratagene). The mutant Mcl-1 Matrix was generated by fusing amino acids
1-58 of N. crassa ATP-synthase to Mcl-1 N-terminal 34 amino acids truncated mutant.
Mcl-1 ATG1 and M92 were derived by mutating the first start codon of Mcl-1 to TGA
stop codon and N-terminal 91 amino acid truncation, respectively.
Ecotropic Retroviral Production and Cell Transduction
Ecotropic retroviruses were produced by co-transfection of packaging plasmids
(pMD-old-Gag-Pol and pCAG4-Eco) and retroviral expressing plasmids to HEK 293T
cells by using FuGene6 (Roche Applied Bioscience). Collected viruses were filtered and
applied on either ESCs or Mcl-1 conditional MEFs together with 10 ug/ml polybrene
(PB, AmericanBio).
Crispr-Cas9 System for Genomic Targeting
Nine guide RNAs were designed close to Mcl-1’s genomic start codon and amino
acid 10 isoleucine, 11 glycine and paired with the DNA target directly upstream to a 5’NGG as following:
CrRNA-F1, 5’- GTCCGACCATGTTTGGCCTG -3’;
CrRNA-F2, 5’- GTTTGGCCTGCGGAGAAACG -3’;
CrRNA-F3, 5’- GATGACTTGAACCTGTACTG -3’;
CrRNA-F4, 5’- GCCAGCCTCGGCGCGGGCGG -3’;
CrRNA-R1, 5’- GTCGGACGCCGCAGGCTGAG -3’;
CrRNA-R2, 5’- GTTTCTCCGCAGGCCAAACA -3’;
CrRNA-R3, 5’- ACCGCCGCCCGCGCCGAGGC -3’;
CrRNA-2F, 5’- GCGGGCGGCGGTTCTCCGGC -3’;
CrRNA-2R, 5’- GGCTGGCGCCGCCGCAGTAC -3’.
Then, each of the guide RNA was cloned into the all-in-one Cas9 (BB)-2A-GFP
(Addgene plasmid ID: 48138) through BbsI enzyme site and validated by sequencing
with a universal U6-forward primer:
5’-GAGGGCCTATTTCCCATGATTCC-3’.
Repair templates single-stranded DNA oligonucleotides (ssODNs) containing 5’
and 3’ homologous arms, amino acids 10 aspartic acid, 11 aspartic acid mutations as well
as the mutated CRISPR-Cas9 binding sites were also designed by either symmetric or
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asymmetric strategies and synthesized through IDT (Integrated DNA Technologies) for
making cleavage site amino acid 10, 11 knock-in (CS10,11 KI) mutagenesis as following:
Symmetric ssODN CS10,11 F3M, 5’- CCT GCG GCG TCC GAC CAT GTT
TGG CCT GCG GAG AAA CGC GGT CGA TGA CCT CAA TCT ATA CTG CGG
CGG CGC CAG CCT CGG CGC GGG CGG CGG TTC TCC G -3’;
Asymmetric ssODN CS10, 11 F3M, 5’- CCT CGC GCC GCG CCT TGG CCT
CCT CGG CCA CCA GGC GCG CCC CTG CCG GAG AAC CGC CGC CCG CGC
CGA GGC TGG CGC CGC CGC AGT ATA GAT TGA GGT CAT CGA CCG CGT
TTC TCC GCA GGC CAA ACA TGG TCG GAC G -3’;
Symmetric ssODN CS10,11 R2M, 5’- TTC CCC TCA GCC TGC GGC GTC
CGA CCA TGT TTG GCC TGC GGC GCA ATG CGG TCG ATG ACT TGA ACC
TGT ACT GCG GCG GCG CCA GCC TCG GCG CGG GCG G -3’;
Asymmetric ssODN CS10, 11 R2M, 5’- TTC CGC CTG CCT CCG GTC TGG
AGT CGC GGC CTT CCC CGC TCC TTC CCC TCA GCC TGC GGC GTC CGA
CCA TGT TTG GCC TGC GGC GCA ATG CGG TCG ATG ACT TGA ACC TGT
ACT GCG GCG GCG CCA GCC TCG GCG CG -3’.
Embryonic stem cells (ESCs) F12 were transfected with each guide RNA
containing all-in-one plasmid as well as ssODNs repair template. 48 hours after
transfection, ESCs were sorted for GFP positive cells. After sort, 20,000 cells were
seeded in 10 centimeter (cm) dish and growing as single cell clones. The leftover pool
cells from each individual guide RNA were screened first by T7E1 surveyor nuclease
digestion as well as by immunoblotting. After single cells grew out, they were screened
by both Sanger sequencing and immunoblotting.
Surveyor Nuclease Digestion
DNA was extracted from ESCs for each guide RNA leftover pools. PCR was
performed to amplify targeted Mcl-1 amplicons by using the following primers:
Mcl-1 forward primer, 5’- AACGGCCTTCCTCACTCCTGACTT -3’;
Mcl-1 reverse primer, 5’- AGTAGCGCGAGATGATCTCCAGCGA -3’.
Further the PCR amplified targeted sequences were denatured and re-hybridized.
PCR reactions were subjected to endonuclease T7E1 digestion which would recognize
the heteroduplexes formed by either wild-type and mutant sequences or two different
mutant amplicons. The final PCR reactions treated in the absence or presence of T7E1
were evaluated by agarose gels.
Immunoblotting, Co-immunoprecipitation, and Antibodies
Cells or tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer (50
mM Tris-HCL at pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1% sodium
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deoxycholate, 0.1% SDS) containing protease inhibitors (Cat: 11836145001, Roche) on
ice for 30 minutes. Lysates were then collected by centrifugation and protein
concentrations were measured by BCA assay (Pierce) with standard curve. 20
micrograms (ug) of each protein samples was loaded on 10% NuPAGE Bis-Tris gels
(Invitrogen) and MOPS SDS served as the trailing ion in the running buffer. For coimmunoprecipitation assays, whole cell lysates (WCLs) were collected and coupled with
anti-BIM rat monoclonal antibody (Millipore) for one hour, and then precipitated with
protein A/G-plus agarose (Santa Cruz Biotechnology). Immunocomplexes and postimmunoprecipitated supernatants were subjected to 10% NuPAGE Bis-Tris gels
(Invitrogen), transferred to PVDF (Millipore) and developed by using Western Lightning
ECL Pro (Perkin Elmer) on a LI-COR Odyssey (LI-COR, NB). The following antibodies
were used: anti-MCL-1 (Rockland Immunochemical), anti-Actin (Millipore), anti-OPA-1
(BD Biosciences), anti-MnSOD (BD Biosciences), anti-BIM (BD Biosciences), antimBCL-2 (Clone 3F11, gift of S. Korsmeyer), anti-hBCL-2 (Clone 6C8, gift of S.
Korsmeyer), anti-BAX (Millipore), anti-ATP5B (Santa Cruz Biotechnology), antiCaspase 3 (Cell Signaling Technology) and anti-PARP (Cell Signaling Technology).
Genotyping and Sanger Sequencing
Genomic DNA of single ES colonies or tail tissues of individual pups were
extracted in 100 mM Tris-HCl at pH 8.3, 100 mM NaCl, 5 mM EDTA, 1% Triton X-100,
and 100 ug/ml proteinase K. Samples were incubated overnight at 55°C and 85°C for 45
minutes. Debris were removed by 13,000 rpm centrifugation for 10 minutes. Genomic
DNA was amplified by using Mcl-1 forward primer 5’- AACGGCCTTCCTCACTCC
TGACTT -3’ and Mcl-1 reverse primer, 5’- AGTAGCGCGAGATGATCTCCAGCGA 3’. PCR products were purified (Qiagen PCR purification kit) and subjected to Sanger
sequencing by using the same Mcl-1 forward primer. Homozygous mutations were
determined by comparison to mouse Mcl-1 genomic sequences and heterozygous
mutations were determined by filtering out the known sequence of the wild-type allele.
Mass Spectrometry Identification
MCL-1 wild-type (WT) and mutant 30 kD ESCs around 5 million each were
washed with PBS and re-suspended in 0.5 ml hypotonic buffer (20 mM Tris HCl at pH
7.4, 10 mM MgCl2 containing protease inhibitors described previously), and then
homogenized by brief sonication. After short centrifugation at 800g, the supernatant was
taken for ultracentrifuge at 180,000g for 10 min at 4°C. The pellets were dissolved in 50
ul 1% Triton X-100 in PBS containing PIC and centrifuged at 20,000g for 3 minutes.
The supernatant was collected and separated by SDS-PAGE. The bands were cut
from the predicted regions, and then digested by 12.5 ng/ul trypsin in 50 mM NH4HCO3
at pH 8.5. The final peptide samples were loaded to C18 column (75 uM internal
diameter, 10 cm long, 1.9 um resin beads), eluted at 15-40% buffer B gradient (buffer A:
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0.2% formic acid, 5% acetonitrile; buffer B: 0.2% formic acid, 95% acetonitrile) at 300
nl/min for 6 hours on LTQ Orbitrap Velos (Thermo Scientific).
Embryoid Body Formation
Embryoid bodies (EBs) were generated by separating the undifferentiated mouse
ESCs and resuspending 300 cells into 50 ul hanging drops. Two days later, aggregates
were collected and transferred to ultralow attachment dishes with EB culture medium,
consisting of 90% DMEM (Lonza), 10% FBS (Hyclone), 100 U/ml penicillin, 100 ug/ml
streptomycin, 2 mM L-glutamine (all from Invitrogen), and 0.1 mM mercaptoethanol
(Gibco). The medium was changed every other day. EBs were collected by either day 4
or day 10 for further analysis.
Cryosectioning and Immunofluorescent Staining of Embryoid Bodies
Collected embryoid bodies (EBs) were precipitated and mounted in tissue
freezing medium (Triangle Biomed), then saved at -80°C. Cut 10 um thick tissue sections
by using a cryostat (Microm HM 505) onto the microscope slides (Fisher Scientific).
Sections were air dried for 30 minutes at room temperature (RT) and the EBs fixed on the
glass cover slip in 4% paraformaldehyde (PFA) in PBS supplemented with 0.1% Triton
X-100 for 15 minutes at RT, followed by permeabilization with 0.1% Triton X-100 in
PBS for 5 minutes at RT. Cells were blocked with 10% goat serum in PBS. All primary
antibodies were diluted in 3% goat serum in PBS added to slides and incubated overnight
at 4°C. Cells were treated with fluorescently coupled secondary antibody diluted in 3%
goat serum in PBS, goat anti-mouse or goat anti-rabbit (Life Technologies) and were
incubated for 1 hour at RT. Glue containing DAPI (ProLong Gold Antifade Mountant,
Thermo Fisher Scientific) was added onto the EBs and covered by a glass. The glue was
allowed to dry and all images were captured by using microscopy (Zeiss Axioskop II
Plus).
RNA Isolation and Quantification
RNA was extracted from ESCs with TRIzol (Ambion) and reverse transcribed by
using SuperScript III first-strand synthesis kit (Invitrogen). Fast real-time PCR with fast
SYBR green (Bio-Rad) detection was performed by using QuantStudio 7 Flex (Life
Technologies). And the following primers were used:
mSox-2 forward: 5’- GGTTACCTCTTCCTCCCACTCCAG -3’;
mSox-2 reverse: 5’- TCACATGTGCGACAGGGGCAG -3’;
mOct-4 forward: 5’- ATGGCATACTGTGGACCTCA -3’;
mOct-4 reverse: 5’- AGCAGCTTGGCAAACTGTTC -3’;
mSox7 forward: 5’- GACACCTTGGATCAGCTAAGCC -3’;
mSox7 reverse: 5’- CCTCCAGCTCTATGACACACTG-3’;

22

mFgf-5 forward: 5’- AAAGTCAATGGCTCCCACGAA -3’;
mFgf-5 reverse: 5’- GGCACTTGCATGGAGTTTTCC -3’;
mmHox-4 forward: 5’- TGGCGGCACAAGCAGACGAAAG -3’;
mmHox-4 reverse: 5’- GTGAGGTTCACCCGACGTGCGAGA -3’;
mIhh forward: 5’- ACGTGCATTGCTCTGTCAAGT -3’;
mIhh reverse: 5’- CTGGAAAGCTCTCAGCCGGTT -3’;
mGapdh forward: 5’- TGTGTCCGTCGTGGATCTGA -3’;
mGapdh reverse: 5’- CCTGCTTCACCACCTTCTTGA -3’.
Double delta Ct analysis was used to calculate the mRNA levels. The assay was
done in triplicate for each sample.
Teratoma Formation Assay
For teratoma induction, one million of ESCs were injected intramuscularly into
immunodeficient nude mice. For Mcl-1flox/flox CreERT2 ESCs, tamoxifen or vehicle gavage
was performed one week after ESCs injection, five days in a row, to delete the
endogenous MCL-1. Tumor growth was observed and palpated every day. When any of
the tumors reached around twenty percent of surface area of the recipients, all the
teratomas were harvested at the same time. Images of teratomas were taken and pieces of
teratoma tissues were cut for histology, PCR or immunoblot analysis.
Histology
Teratoma tissues were fixed in 10% neutral buffered formalin, embedded in
paraffin and cut into 4-um thickness of sections by using HM500M cryostat (Microm).
The embedded sections were stained by hematoxylin and eosin (H&E) stain. Three germ
layer tissues of teratoma samples were reviewed by the pathologist Dr. Jerold Rehg at St.
Jude Children’s Research Hospital.
Cell Death Assay
F12 ESCs or Mcl-1flox/flox CreERT2 MEFs stably expressing murine stem cell virus
MSCV-puro vector, WT MCL-1, ATG1 or M92 grown in the presence of tamoxifen for
48 hours were treated with staurosporine at increasing doses for 16 hours (Calbiochem).
Cell viability was determined by Annexin-V-APC and propidium iodide (PI) (BD
Biosciences) staining through flow cytometry FACSCantoII (BD Biosciences).
Subcellular Fractionation and Proteolysis of Heavy Membrane Fraction
ESCs or MEFs were swollen in ice-cold mitochondria isolation (MIB) buffer (200
mM mannitol, 68 mM sucrose, 10 mM HEPES-KOH at pH 7.4, 10 mM KCl, 1 mM
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EDTA, 1 mM EGTA, 0.1% BSA) containing protease inhibitor cocktail (PIC) for 30
minutes and then homogenized 30 times with a 30 gauge needle. The non-lysed cells and
nuclei were sedimented by centrifugation at 600g for 10 minutes and disposed. The
collected supernatant was centrifuged at 5,500g for 15 minutes and the pellet was the
heavy membrane fraction. The supernatant again was centrifuged at 100,000g for 30
minutes and the soluble fraction contained the purified cytosolic proteins.
The isolated heavy membrane (HM) fraction, mainly mitochondria, was measured
by Bradford assay for protein concentration. HM (40 ug) were set up with the following
treatment: proteinase K (0.2 mg/ml), 20 mM KCl (osmotic shock), proteinase K (0.2
mg/ml) plus 20 mM KCl (osmotic shock), 1% SDS (detergent for membrane
solubilization) for 60 minutes on ice. Proteins were further precipitated by
tricholoroacetic acid (TCA) (Sigma) and subjected to immunoblotting analysis.
Zygote Injection
Freshly fertilized E0.5 post-coital single cell embryos (zygotes) were obtained
from freshly weaned ovulated C57BL/6J mice. Recovered zygotes were cultured until
both pronuclei were microscopically visible. Approximately 150-200 zygotes were
transferred to a microdrop of M2 medium (Sigma-Aldrich) on a microinjection slide
overlaid with mineral oil and the slide was placed on an inverted microscopy.
Microinjection pipettes were filled with 100 ng/ul guide RNA with scaffold, 50 ng/ul
Cas9 mRNA and 200 ng/ul ssODN. Each embryo was held with light suction by a
holding pipette and rotated until one of the two pronuclei was visible. Then, mRNA
mixture was injected into the cytoplasm and DNA into one pronucleus. Successful
injection of a few picoliters (pl) of solution was observed by the visible swelling of the
pronucleus or presence of a jet stream in the cytoplasm. Microinjected zygotes were
surgically transferred to the infundibula of 0.5-day-post-coital pseudopregnant foster
mothers on the same day, 20 to 25 zygotes per recipient. Full-term pups were obtained by
natural labor about 19 days later. All the zygote microinjection procedures were carried
out by the transgenic core facility at St. Jude Children’s Research Hospital.
DNA Deep Sequencing
DNA of toes from zygote injection founders was collected. Endogenous Mcl-1
amplicons of exon 1 around start codon were amplified by the same Mcl-1 forward and
reverse primers described earlier. Amplicons from different samples were mixed and
barcoded by another round of PCR using a Nextera Index Kit and the adaptor primers
used were Nextera forward 5’- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 3’ and reverse 5’- GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG -3’. The
library prepared from the final PCR products of indexed samples was subjected to a 300
bp-paired-end sequencing with Illumina Miseq for the targeted region. After quality
control, reads of each sample were aligned to the sequences of targeted region and
compared with the same sequencing run generated from control sample with more than
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10,000x depth of coverage. After deep sequencing, an in-house Perl script was used to
analyze and summarize the allele frequencies of Mcl-1 variants.
Microarray Analysis and GSEA
Affymetrix Mouse Gene 2.0 ST arrays were used to assay gene expression
analysis from RNA samples. Mcl-1flox/flox CreERT2 ESCs treated with tamoxifen for 48
hours were statistically tested by unequal variance t test to the DMSO control (3
replicates). Gene set enrichment analysis (GSEA) (version 2.3.3) was performed by
comparing Mcl-1flox/flox CreERT2 ESCs treated with tamoxifen versus DMSO control.
Statistics
Growth curves significance was calculated by using the two-tailed Student t test
and p values are denoted in the figure legends. GSEA comparing Mcl-1flox/flox CreERT2
ESCs treated with tamoxifen versus DMSO control was statistically calculated by
unequal variance t test.
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CHAPTER 3.

RESULTS

CRISPR-Cas9 Targeting of Genomic Mcl-1 to Generate Mcl-1 Mutants
To target genomic Mcl-1 by CRISPR-Cas9, we designed 9 individual guide RNAs
around the start codon of Mcl-1 and each of the gRNAs was directly upstream of a
requisite 5’-NGG. A single-stranded DNA oligonucleotide (ssODN) containing both 5’
and 3’ homologous arms and amino acids 10, 11 mutations was provided as a repair
template. Our preliminary data suggested that mutagenesis of amino acids 10, 11 from
isoleucine, glycine to aspartic acid abrogates MCL-1’s importation to the mitochondrial
matrix, only maintaining its anti-apoptotic species. For in vitro targeting, we chose
embryonic stem cells (ESCs) because ESCs form self-renewing compact colonies from
single cells, which allows us to screen individual mutation, and ESCs are pluripotent cells
that can differentiate to three germ cell layers: ectoderm as neurons, mesoderm as
cardiomyocytes, and endoderm like gut tissues. More importantly, when injected into
blastocysts, those blastocysts can be transferred into foster mothers to make chimeric
recipient pups.
We transfected the F12 ESCs with our all-in-one CRISPR-Cas9-GFP plasmid as
well as an ssODN containing amino acids 10, 11 mutations as the repair template, and
sorted GFP positive cells. The CRISPR-Cas9 transfected GFP positive cells were seeded
at low density 20,000 cells in 10 cm dish to grow as single cell clones. The left over
targeted pool of cells were first analyzed by Surveyor endonuclease assay T7E1, which is
an enzyme mismatch cleavage assay used to detect small mismatches, insertions or
deletions. By comparing the amplicons in the presence or absence of T7E1, WT control
showed no observable cleaved band (Figure 3-1A). Among the 9 individual crRNAs as
well as a paired CRISPR-RNA (crRNAs), four of them, crRNA-F3, crRNA-R1, crRNAR2, crRNA-R3, showed obvious cleavages, indicating the presence of mutant DNAs. The
mutation efficiencies were roughly estimated by the densitometry of decreased full-length
band in the presence of T7E1 divided by the full-length band in the absence of T7E1
enzyme (Figure 3-1A). Immunoblotting of the targeted pool cells showed reduced
expression levels of full-length MCL-1 in crRNA-F3, crRNA-R1, crRNA-R2, and
crRNA-R3, which is consistent with T7E1 assay (Figure 3-1B).
After the single cells grew out, we extracted the DNA and performed PCR for the
amplicons from ESC clones from the most efficient four gRNAs. All successfully
amplified fragments were sent for Sanger sequencing. Total mutation efficiencies ranged
from 75% to 96.2% among the four gRNAs and bi-allelic mutation efficiencies were
from 31.2% to almost 90% (Table 3-1). MCL-1 amino acids 10, 11 replacement mutant
(CS10, 11 MCL-1) was not generated during our in vitro screening. We hypothesize is that
the bi-allelic mutation efficiency was high and that cells were inclined to repair through
the NHEJ pathway.
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Figure 3-1. Pool validation of CRISPR-Cas9 targeting efficiency
(A) PCR amplified targeted amplicons from each guide RNA pool ESCs were treated in
the absence or presence of endonuclease T7E1. The mutation efficiency was calculated
by the ratio of decrease full-length band density divided by untreated full-length band
density estimated by densitometry. (B) Expression level of full-length MCL-1 in each
guide RNA pool ESCs by immunoblotting. α-Actin was used as loading control.
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Table 3-1.
Summary of F12 ESCs transfected with CRISPR-Cas9 targeting on
genomic Mcl-1
CRISPR
RNA
crRNA F3
crRNA R1
crRNA R2
crRNA R3

Clones
Screened
48
48
48
48

Clones
Amplified
35
25
16
27

Total
Efficiency
90%
75%
75%
96.2%

Mono-allelic
Efficiency
10%
43.8%
33.3%
7.7%

Bi-allelic
Efficiency
80%
31.2%
41.7%
88.5%

DNAs extracted from single ESC clones from the four highest mutation efficiency guide
RNA groups (F3, R1, R2, and R3), validated from previous T7E1 and pool
immunoblotting. DNAs were amplified for the CRISPR-Cas9 targeted amplicons and
sent for Sanger sequencing. Homozygous mutations were determined by comparison to
mouse Mcl-1 genomic sequences. Heterozygous mutations were determined by filtering
out the known sequence of the wild-type allele.
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At the protein level, large deletion on both alleles disrupting start codon of Mcl-1
all generated a truncated form of MCL-1 rather than a complete knock out. Full-length
MCL-1 is around 38 kD and the truncated mutant was around 30 kD (Figure 3-2A). To
reveal whether 30 kD starts from the second methionine initiation, we performed mass
spectrometry (MS) N-terminal identification. Protein lysates of the enriched heavy
membrane from Wild-type (WT) and 30 kD mutant ESCs were loaded on SDS-PAGE gel
and the gel bands around 38 kD for WT and 30 kD for mutant ESCs were cut for
identification (Figure 3-2B). The proteolytic fragments of the N-terminus were identified
according to their mass-to-charge ratio. The data indicate that when disrupting the start
codon of Mcl-1 on both alleles, MCL-1 will initiate translation through the second
methionine (M92) and produce a 30 kD truncated protein (Figure 3-2C and D).
Mutant ESCs Show a “Sick” Phenotype and Fail to Differentiate to Broad Lineages
Phenotypically, when seeding equal number of cells during culture, WT ESCs
presented as big, healthy clones. As WT control we used the CRISPR-Cas9 targeted GFP
negative sorted cells (Figure 3-3). However, 30 kD ESCs presented as much smaller
clones with low attachment (Figure 3-3).
To evaluate the pluripotency as well as the differentiation capacity of the mutant
ESCs, embryoid body (EB) assay was performed. During the routine culture of ESCs in
the presence of leukemia inhibitory factor (LIF) which is used to maintain ESCs’
pluripotency, ESCs present as typical compact clones with undifferentiated cells. EBs are
generated by separating the undifferentiated ESCs into hanging drops and transferred to
ultralow attachment dishes lacking LIF. Cells will aggregate at the bottom of the drop. In
the absence of LIF, the well-organized EBs will spontaneously differentiate toward the
different germ lineages. They begin with a single extraembryonic endoderm layer which
is BMI-1, DAB-2 positive and extraembryonic endoderm surrounds the pluripotent
epiblast cells which are OCT-4 positive. Other cells within the inner cell mass are
composed of three germ cell lineages, ectoderm, mesoderm, endoderm, as well as the
apoptotic cells.
In response to the differentiation signals (absence of LIF), EBs often form cystic
cavities, where the interior cells undergo apoptosis while the other cells migrate as well
as differentiate to specific lineages. Therefore, cavitation is the relatively early event and
the characteristic feature of the EBs undergoing differentiation. On day 4, we started to
observe the beginning of a cavity in the WT control EBs, represented by the bright,
transparent regions. This was not found among the different EBs with 30 kD MCL-1
protein (Figure 3-4). In order to define whether it is a delay or a completely failed
differentiation, EBs were harvested at day 10 and immunofluorescent (IF) staining was
performed on the cryosections of EBs to look at the markers for extraembryonic
endoderm as well as epiblast cells. The IF data suggested that DAB-2, an extraembryonic
endoderm marker, was expressed at the periphery of WT EBs, which surrounded the
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Figure 3-2. Mass spectrometry N-terminal identification of mutant MCL-1
(A) Immunoblotting of the enriched membrane protein fraction from wild-type MCL-1
and mutant 30 kD MCL-1 mouse ESCs was performed to verify MCL-1 protein existence
and its localization against the protein ladder (BenchMark, Life Technologies). (B) SDSPAGE of these two samples to excise the gel bands (boxed) for identification by mass
spectrometry (MS). (C) The amino acid sequence of mouse MCL-1. The traditional and
the hypothetical methionine “M” at the translation initiation sites were highlighted. The
peptide to be identified by MS was underlined. (D) The mass spectrum of the N-terminal
peptide of the mutant 30 kD MCL-1. Product ions (fragments from the peptide) were
indicated by arrows with measured mass-to-charge ratio (m/z). All matched product ions
were also shown in the peptide. Note: the methionine of this N-terminal peptide was
removed, and the next amino acid alanine was acetylated.
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Figure 3-3. Mutant ESCs present a “sick” phenotype in culture
Wild-type ESCs and different lines of 30 kD mutant ESCs (Cl 005, Cl 016, Cl 061, Cl
071, and Cl 098) were seeded as equal number of cells in culture. The phenotype of cells
were observed and captured by inverted microscopy (Nikon Eclipse TS100).
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Figure 3-4. Embryoid body spontaneous differentiation of ESCs
WT or different lines of mutant 30 kD ESCs (Cl 005, Cl 016, Cl 061, Cl 071, and Cl 098)
were dissociated into hanging drops and transferred to ultralow attachment dishes in the
absence of leukemia inhibitory factor (LIF). At day 4, embryoid body (EB) formation
was observed and captured by inverted microscopy (Nikon Eclipse TS100).
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OCT-4 (a pluripotent marker) positive epiblast cells. Overlay showed a nice ring, halolike structure. However, for the 30 kD mutant EBs, the OCT-4 positive cells were
observed, but few DAB-2 positive cells located at the periphery, indicating a defect of 30
kD ESCs to differentiate to extraembryonic endoderm, which is consistent with the
trophectoderm defect during peri-implantation stage of Mcl-1-null embryos
(Figure 3-5A). RNAs from WT and 30 kD mutant EBs were extracted at day 4 and
quantitative real-time PCR (qPCR) was performed to assess the markers from each
lineage. qPCR suggested a broader differentiation defects in 30 kD mutant EBs compared
with WT, showing dramatic decreased levels of Sry-related high-mobility group box 7
(SOX7), another extraembryonic endoderm marker, fibroblast growth factor 5 (FGF5), a
ectoderm marker, paired related homeobox 1 (mHOX), a mesoderm marker, and Indian
hedgehog (IHH), an endoderm marker (Figure 3-5B). These data, taken together,
indicate that N-terminal truncated MCL-1 ESCs present as a sick phenotype and fail to
differentiate to broad lineages, including extraembryonic endoderm, ectoderm,
mesoderm, and endoderm.
Teratoma formation assay is an in vivo assay to test the pluripotency of ESCs and
their capability of differentiation. One million WT control ESCs or 30 kD mutant ESCs
were injected into the flank of nude mice: two out of three WT ESCs gave rise to big
teratomas 25 days post-implantation (Figure 3-6A). However, 30 kD ESCs failed to give
rise to any size tumors at the same given time (Figure 3-6A). In order to test whether the
effect is MCL-1 specific and not random off-target effect in one special ES clone, one
million of the targeted pool ESCs were injected into the flank of nude mice. Three out of
four low efficient CRISPR-targeted pool ESCs gave rise to teratomas 25 days post
implantation, while only one out of four high efficient pool cells produced a tiny tumor
when harvested at the same time (Figure 3-6A). Hematoxylin and eosin (H&E) stain of
WT control teratoma showed tissues from all three germ lineages, surface ectoderm as
the keratinized epithelial, neural ectoderm as neuronal rosettes, mesoderm such as
cartilages as well as the striated muscles, and endoderm showing as the respiratory
epithelial with mucus cells and cilia (Figure 3-6B). These data, consistent with the in
vitro differentiation assay, suggested that N-terminal truncated mutants ESCs fail to
differentiate to broad germ lineages in vivo.
Mutant MCL-1 Is Capable of Antagonizing Cell Death and Localizes to the Outer
Mitochondrial Membrane
MCL-1 is well-known for its anti-apoptotic function, therefore it is important to
test whether 30 kD mutant ESCs can antagonize cell death. Staurosporine, a broad kinase
inhibitor capable of inducing apoptosis, was added at different doses on WT ESCs and
different lines of 30 kD mutants. The curves representing the percentage of annexin
positive cells at different doses of staurosporine didn’t show obvious differences among
WT ESCs and several 30 kD ESC lines (Figure 3-7A). The subcellular localization data
showed that WT MCL-1 and 30 kD mutant MCL-1 were enriched at the heavy membrane
(HM), indicating their mitochondrial localization (Figure 3-7B). Further, proteinase K
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Figure 3-5. 30 kD mutant ESCs show broad differentiation defects
(A) Expression of DAB-2 and OCT-4 in the embryoid body day 10. Cryosections of
spontaneous differentiation embryoid bodies (WT versus two lines of 30 kD) at day 10
were immunostained with anti-DAB-2 and anti-OCT-4 antibodies. Sections were
counterstained with the DNA dye DAPI. All images were captured by using a
microscopy (Zeiss Axioskop II Plus). (B) Real-time PCR with fast SYBR green (BioRad) detection was performed by using QuantStudio 7 Flex (Life technologies). Primers
used were Sox2 (pluripotency marker), Oct4 (pluripotency marker), Sox7
(extraembryonic endoderm), Fgf5 (ectoderm), mHox (mesoderm), Ihh (endoderm).
Double delta Ct analysis was used to calculate the mRNA levels. The assay was done in
triplicate for each sample. Error bars represent the standard error of the mean.

36

Figure 3-6. 30 kD mutant ESCs fail to give rise to teratoma
(A) Teratoma formation of WT, 30 kD ESCs and low versus high efficient CRISPR-Cas9
targeted pool ESCs. One million ESCs were injected into the flank of each
immunodeficient recipient and tumors were harvested 25 days post implantation. (B)
H&E stain of WT teratomas showed tissues from all three germ layers, I (low
magnification), II-VI (high magnification), II (surface ectoderm as the keratinized
epithelial), III (neural ectoderm as neuronal rosettes), IV (mesoderm as cartilages), V
(mesoderm as striated muscles), and VI (endoderm showing as the respiratory epithelial
with mucus cells and cilia).

37

Figure 3-7. 30 kD mutant ESCs retain anti-apoptotic function and reside on the
outer mitochondrial membrane
(A) WT ESCs and different lines of 30 kD ESCs were administered indicated doses of
staurosporine for 16 hours after which cell death assay by flow cytometry was
determined. Bars represent the average of 3 independent experiments and the error bars
denote the SEM. (B) Mitochondria enriched, heavy membrane (HM) or cytosol (S100)
fractions were isolated from WT and 30 kD ESCs. Whole cell lysates (WCL) acted as a
control. Fractions were resolved and immunoblotted for MCL-1. OPA-1, MnSOD, or
BIM worked as intermitochondrial membrane, inner matrix or cytosolic marker,
respectively. (C) Mitochondria isolated from WT or 30 kD ESCs were subjected to
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial
membrane (OMM), and detergent SDS was used to disrupt both inner and outer
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses.
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assay was carried out on the isolated mitochondria. Upper and middle bands of MCL-1
were both sensitive to proteinase K digestion, but the lower band was resistant even
under the osmotic shock. This is consistent with our previous finding suggesting that WT
MCL-1 retains outer mitochondrial membrane and matrix dual localizations
(Figure 3-7C). However, 30 kD mutant MCL-1 only has one band and was sensitive to
proteinase K cleavage, indicating that it only resides on the outer mitochondrial
membrane (Figure 3-7C).
To further evaluate the anti-apoptotic function and the subcellular localization of
30 kD mutant MCL-1, our inducible mouse embryonic fibroblasts (MEFs) were utilized.
The second methionine 30 kD mutant MCL-1 was made by either mutating the first
methionine to TGA stop code called ATG1, or by truncation of the N-terminal 91 amino
acids named M92. MSCV-puro vector, WT MCL-1, ATG1 and M92 were overexpressed
to Mcl-1flox/flox CREERT2 SV40 transformed MEFs and then selected by puromycin. After
the stable cell lines were established, they were treated with tamoxifen for 48 hours.
Immunoblotting showed the endogenous MCL-1 was completely deleted and WT MCL-1
as well as ATG1, M92 mutant MCL-1 were well expressed (Figure 3-8A). Cell death
assay by staurosporine at different doses was repeated. MCL-1-deleted MEFs
overexpressing the empty vector were sensitive to death stimuli and dramatic cell death
was achieved at relative lower staurosporine doses (Figure 3-8B). MCL-1 deleted MEFs
overexpressing either WT MCL-1, ATG1 or M92 exhibited resistance to cell death
stimuli (Figure 3-8B). One mechanism of MCL-1’s anti-apoptotic role is to bind with
the pro-apoptotic death sensor BIM by using its hydrophobic groove to block BAX/BAK
activation. Further, BIM immunoprecipitation (IP) experiment revealed that ATG1 and
M92 were capable of binding to BIM like the upper anti-apoptotic MCL-1 species
(Figure 3-8C). Consistent with the proteinase K assay in ESCs, in the inducible MEFs
system WT MCL-1 retained its dual subcellular localization by presenting with both
sensitive upper band and resistant lower band to proteinase K. In contrast, both ATG1
and M92 exhibited one band which was sensitive to enzyme digestion, further suggesting
its only outer mitochondrial membrane localization (Figure 3-8D).
Establish Mcl-1flox/flox CREERT2 ESCs for Rescue Experiment
To rescue the differentiation defect from mutant MCL-1, Mcl-1flox/flox CREERT2
ESCs were derived as well as Mcl-1flox/WT CREERT2 and Mcl-1flox/flox controls.
Immunoblotting data suggested endogenous MCL-1 was well deleted 48 hours after
tamoxifen treatment on both Mcl-1flox/flox CREERT2 ESCs and embryoid bodies (EBs) day
4 (Figure 3-9A). Mcl-1flox/WT CREERT2 treated with tamoxifen showed decreased level of
MCL-1 compared with Mcl-1flox/WT CREERT2 vehicle treated (Figure 3-9A). When seeded
equal number of cells in culture in the presence or absence of tamoxifen and followed for
growth, tamoxifen treated Mcl-1flox/flox CREERT2 ESCs stopped expanding in culture while
Mcl-1flox/flox CREERT2 ESCs untreated as well as Mcl-1flox/flox regardless of the presence of
tamoxifen showed exponential growth curve (Figure 3-9B). Mcl-1flox/WT CREERT2 treated
with tamoxifen exhibited slower growth rate compared with Mcl-1flox/WT CREERT2 in the
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Figure 3-8. Generation of inducible MEFs overexpressing 30 kD mutant for cell
death and subcellular localization analyses
(A) Western blot of the Mcl-1flox/flox CREERT2 SV40 transformed MEFs stably
overexpressing MSCV-puro vector, WT MCL-1, ATG1, and M92 treated with tamoxifen
for 48 hours for anti-MCL-1. Anti-α-actin acted as a loading control. (B) Mcl-1flox/flox
CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro vector, WT MCL1, ATG1, and M92 treated with tamoxifen for 48 hours were administered indicated
doses of staurosporine for 16 hours after which cell death assay by flow cytometry was
determined. Bars represent the average of 3 independent experiments and the error bars
denote the SEM. (C) Whole cell lysates (WCLs) of Mcl-1flox/flox CREERT2 SV40
transformed MEFs stably overexpressing MSCV-puro vector, WT MCL-1, ATG1, and
M92 treated with tamoxifen for 48 hours were collected and coupled with anti-BIM rat
monoclonal antibody, and then precipitated with protein A/G-plus agarose.
Immunocomplexes and post-immnoprecipitated supernatants were subjected to
immunoblotting for anti-MCL-1 and anti-BIM. (D) Mitochondria isolated from Mcl1flox/flox CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro vector, WT
MCL-1, ATG1, and M92 treated with tamoxifen for 48 hours were subjected to
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial
membrane (OMM), and detergent SDS was used to disrupt both inner and outer
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses.
OPA-1, MnSOD, or mouse BCL-2 worked as intermitochondrial membrane, inner matrix
or cytosolic marker, respectively.
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Figure 3-9. Mcl-1-deleted Mcl-1flox/flox CREERT2 ESCs fail to proliferate in vitro
and give rise to teratoma in vivo
(A) Western blot of the Mcl-1flox/flox CREERT2, Mcl-1flox/flox, and Mcl-1flox/WT CREERT2
ESCs in the absence and presence of tamoxifen for 48 hours. Anti-α-actin acted as a
loading control. (B) Mcl-1flox/flox CREERT2, Mcl-1flox/flox, and Mcl-1flox/WT CREERT2 ESCs in
the absence and presence of tamoxifen were seeded equal number of cells in culture and
followed and plotted for growth curves. Bars represent the average of 3 independent
experiments and the error bars denote the SEM. #p>0.05 and **p<0.01 as determined by
two-tailed Student t test. (C) Teratoma formation of Mcl-1flox/flox CREERT2, Mcl-1flox/flox,
and Mcl-1flox/WT CREERT2 ESCs in the absence and presence of tamoxifen. One million of
each ESCs were injected into the flank of immunodeficient recipient and tumors were
palpated every the other day. Mcl-1flox/flox and Mcl-1flox/WT CREERT2 teratomas regardless
of tamoxifen treatment were harvested 25 days post implantation, while Mcl-1flox/flox
CREERT2 teratomas were harvested 39 days post implantation.
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absence of tamoxifen (Figure 3-9B). To test whether the Mcl-1flox/flox CREERT2 ESCs we
generated retained pluripotency and response to tamoxifen in vivo, one million of ESCs
were injected into the flank of nude mice and vehicle or tamoxifen gavage was performed
one week post the implantation, five days in a row. All four immunodeficient recipients
receiving Mcl-1flox/flox CREERT2 ESCs treated with vehicle had teratomas at 39 days after
implantation. However, none of the recipients transplanted with Mcl-1flox/flox CREERT2 and
treated with tamoxifen had observable tumors at the same time (Figure 3-9C). Mcl1flox/WT CREERT2 and Mcl-1flox/flox ESCs treated either with vehicle or tamoxifen gave rise
to big size teratomas at 25 days after injection (Figure 3-9C). These data taken together
suggest that MCL-1 is required for ESCs proliferation and differentiation to multiple
germ lineages. ESCs with one deleted allele of MCL-1 showed attenuated growth rate in
culture.
We further made mutants to dissect MCL-1’s two isoforms for ESCs rescue
purpose. CS10, 11 and CS33, 34 MCL-1 were generated by either mutagenesis of amino acids
at position 10, 11 from isoleucine, glycine to aspartic acid, aspartic acid or amino acids at
position 33, 34 from leucine, valine to aspartic acid, aspartic acid (Figure 3-10A). To
generate a MCL-1 mutant that only restricts within matrix, we fused the mitochondrial
targeting sequence from ATP synthase to N-terminal 34 amino acids truncated MCL-1,
call Matrix MCL-1 (Figure 3-10A). Consistent with our hypothesis, compared with WT
MCL-1’s dual localization, Matrix MCL-1 only formed one band which was completely
resistant to enzyme digestion even under the osmotic shock, suggesting its mitochondrial
matrix only localization (Figure 3-10B). Both CS10, 11 and CS33, 34 MCL-1 were sensitive
to proteinase K, therefore they only reside on the outer mitochondrial membrane
(Figure 3-10B). And our previous functional studies indicated that two species of MCL-1
retain different functions due to their distinct localization. Outer mitochondrial membrane
localized MCL-1 performs the classical anti-apoptotic function by antagonizing BAX and
BAK, while matrix localized MCL-1 does not possess anti-apoptotic activity, but plays a
role in maintaining mitochondrial ultrastructure, promoting mitochondrial fusion and
fission, supporting the assembly of ATP synthase oligomers and oxidative
phosphorylation [38].
To evaluate which MCL-1 function would rescue the defects of ESCs, MSCV-IGFP (MIG) Vector, WT MCL-1, CS10,11, Matrix, 30 kD MCL-1 or hBCL-2 was
overexpressed onto Mcl-1flox/flox CREERT2 ESCs by viral transduction. Tamoxifen or
vehicle was performed on each of them and cell lysates were harvested at either day 3
and 6 to check the endogenous MCL-1 deletion efficiency as well as the exogenous
overexpression level. The Mcl-1flox/flox CREERT2 ESCs overexpressing MIG vector
showed good deletion efficiency on day 3 after tamoxifen treatment, however at day 6,
the endogenous MCL-1 could not be deleted in the presence of tamoxifen, indicating a
long-term selection pressure against MCL-1 loss (Figure 3-11A). This finding is
consistent with our previous publication that there was strong selection against MCL-1
loss during BCL-ABL pre-B leukemia transformation in vitro and in vivo [110]. WT,
CS10, 11, Matrix, 30 kD MCL-1 and hBCL-2 were well-expressed and the endogenous
MCL-1 in these groups were well-deleted (Figure 3-11A). When seeded equal number of
cells in the presence or absence of tamoxifen in culture, Mcl-1flox/flox CREERT2 ESCs
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Figure 3-10. Dissect MCL-1’s two isoforms for rescue experiments
(A) Schematic illustration of cleavage sites mutants and Matrix mutant of MCL-1. CS10,
11
and CS33, 34 MCL-1 were generated by either mutagenesis of amino acids at position 10,
11 from isoleucine, glycine to aspartic acid, aspartic acid or amino acids at position 33,
34 from leucine, valine to aspartic acid, aspartic acid. Matrix MCL-1 was generated by
fusing the mitochondrial targeting sequence from ATP synthase to N-terminal 34 amino
acids truncated MCL-1. (B) Mitochondria isolated from Mcl-1-deleted Mcl-1flox/flox
CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro WT MCL-1, CS10,
11
, CS33, 34 , Matrix MCL-1 treated with tamoxifen for 48 hours were subjected to
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial
membrane (OMM), and detergent SDS was used to disrupt both inner and outer
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses.
OPA-1, MnSOD, or mouse BCL-2 worked as intermitochondrial membrane, inner matrix
or cytosolic marker, respectively.
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Figure 3-11. Put back MCL-1 mutants for proliferation rescue
(A) Western blot of Mcl-1flox/flox CREERT2 ESCs overexpressing MIG Vector with or
without tamoxifen, WT MCL-1, CS10, 11, Matrix, 30 kD MCL-1, and hBCL2 with
tamoxifen for either 3 days or 6 days. (B) Mcl-1flox/flox CREERT2 ESCs overexpressing
MIG Vector with or without tamoxifen, WT MCL-1, CS10, 11, Matrix, 30 kD MCL-1, and
hBCL2 with tamoxifen were seeded equal number of cells and growth curves were
plotted. Bars represent the average of 3 independent experiments and the error bars
denote the SEM. #p>0.05, *p<0.05, and **p<0.01 as determined by two-tailed Student t
test when compared to Mcl-1flox/flox CREERT2 ESCs overexpressing Vector treated with
tamoxifen.
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overexpressing MIG vector in the absence of tamoxifen showed exponential growth,
while the same cells treated with tamoxifen failed to proliferate (Figure 3-11B). All
mutants with anti-apoptotic function, WT, CS10, 11, 30 kD MCL-1 and hBCL-2, rescued
the growth of the Mcl-1-deleted MIG vector overexpressing ESCs. Matrix MCL-1,
without anti-apoptotic activity, failed to rescue the proliferation (Figure 3-11B). These
data, taken together, suggest that anti-apoptotic function of MCL-1 is required for ESCs
survival and proliferation.
To examine whether different MCL-1 species can rescue the differentiation
defect, one million of each ESCs were injected into the flank of nude mice and either
tamoxifen or vehicle was performed one week after implantation, five days in a row. Mcl1flox/flox CREERT2 ESCs overexpressing MIG vector treated with vehicle gave rise to big
size teratomas 35 days after the injection (row 1), while the same cells treated with
tamoxifen failed to generate any tumors during the same period (not shown)
(Figure 3-12A). All three immunodeficient recipients receiving tamoxifen treated Mcl1flox/flox CREERT2 ESCs overexpressing MIG WT MCL-1 had big size teratomas (row 2),
however, adding back the 30 kD MCL-1 mutant failed to give rise to any size teratomas
within the same time frame (data not shown) (Figure 3-12A). Mcl-1flox/flox CREERT2 ESCs
overexpressing anti-apoptotic only mutant CS10, 11 MCL-1 or hBCL2 treated with
tamoxifen generated smaller teratomas with pale color (rows 3 and 5). When the Matrix
form was added back only one out of three gave rise to pale teratoma 35 days after
implantation (row 4) (Figure 3-12A). According to histology review, teratomas from all
recipients receiving Mcl-1flox/flox CREERT2 ESCs overexpressing the MIG vector treated
with vehicle and overexpressing the WT MCL-1 treated with tamoxifen had all three
germ layers, including neuroectoderm tissues, surface ectoderm epidermal elements,
endoderm tissues like ciliated respiratory epithelium and mesoderm tissues such as
striated muscles as well as cartilages. However, teratomas harvested from recipients
transplanted with Mcl-1flox/flox CREERT2 ESCs overexpressing the anti-apoptotic only
mutant CS10, 11 of MCL-1 treated with tamoxifen failed to give rise to distinct three germ
layer tissues, but contained foci suggestive of vast amount of primitive undifferentiated
tissues. PCR for deleted alleles from teratomas showed distinct deletion bands in all
samples treated with tamoxifen (Figure 3-12B). And further immunoblotting from
teratoma samples exhibited good deletion efficiency and overexpression levels except
that one teratoma sample harvested from the recipient receiving tamoxifen treated Mcl1flox/flox CREERT2 ESCs overexpressing Matrix showed observable endogenous MCL-1
bands (Figure 3-12C). These data, taken together, indicate that exogenous WT MCL-1
can rescue both the proliferation and differentiation of Mcl-1-deleted ESCs, however,
anti-apoptotic only mutants, CS10, 11, 30 kD MCL-1 and hBCL-2, could only rescue
proliferation. Neither anti-apoptotic only mutants nor Matrix species of MCL-1 were able
to fully rescue the differentiation in the Mcl-1-deficient ESCs.
Zygote Injection to Generate MCL-1 Mutant Mice
To study MCL-1 mutants (CS10, 11 and 30 kD MCL-1) in a more physiological
setting, we performed zygote injection to generate mutants knock-in mice.
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Figure 3-12. Teratoma formation needs both forms of MCL-1
(A) One million Mcl-1flox/flox CREERT2 ESCs overexpressing either MIG Vector, WT
MCL-1, CS10, 11, Matrix, 30 kD MCL-1, or hBCL2 ESCs were injected into the flank of
immunodeficient recipient and tamoxifen gavage was performed one week after the
implantation, five days in a row. Tumors were palpated every the other day and all the
tumors were harvested 35 days post implantation. (B) DNA was extracted from each
teratoma lysate and PCR was performed for the deleted allele. (C) Immunoblots from
each teratoma lysates to show endogenous MCL-1 deletion as well as the exogenous
mutant overexpression.
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In vitro transcribed Cas9 mRNA, guide RNA (F3 or R2), and guide RNA related ssODN
were injected into mouse zygotes. The ssODNs consisted of either symmetric or
asymmetric homologous arms, Mcl-1 amino acid 10, 11 mutagenesis, and silent mutation
of CRISPR recognition sites in order to prevent recurrent targeting. The asymmetric
repair template design has been suggested to increase the homologous recombination
efficiency [111]. According to the deep sequencing result of 19 founders’ toe DNAs from
zygote injection, 11 of them had mutations, with either deletion (red bar), insertion (green
bar) or replacement mutation (orange color). The total mutation efficiency in founders
was 58% and 31.5%, 10.5% and 16% for deletion, insertion and replacement mutation,
respectively (Figure 3-13). Two founders, xy007 and xy009, obtained the desired
mutagenesis encoding amino acids 10, 11 aspartic acid, aspartic acid to replace the
original wild-type isoleucine, glycine with mutation percentages 3.34% and 14.99%,
respectively. Interestingly, xy012 founder carried a desired CS10, 11 mutation followed by
an in-frame stop codon TAG, which presumably would generate 30 kD KI mice with a
mutated allele frequency of 21.88% (Figure 3-13). Since Cas9 is active as the zygotes
divide, the founders are expected to be germline mosaic and the percentages roughly
represent the mutated allele frequencies (Figure 3-13). We bred the desired CS10,11 KI
founders xy007 and xy009 as well as the KI plus stop codon mouse, presumably 30 kD
KI founder, in the same mouse background C57BL/6J to generate KI F1 generation.
Genomic DNAs extracted from tails of KI F1 pups were amplified and subjected
to Taq I enzyme digestion (Figure 3-14A) and Sanger sequencing (Figure 3-14B). CS10,
11
mutagenesis creates a unique Taq I enzyme site, therefore, KI alleles could be detected
by Taq I cleavage. Compared with uncut, full-length amplicon plus cleavage bands
suggested KI heterozygous in the presence of Taq I (Figure 3-14A). Wild-type from
Sanger sequencing were determined by comparison to mouse Mcl-1 genomic sequences
and heterozygous mutations were determined by filtering out the known sequence of the
WT allele (Figure 3-14B). CS10, 11 KI F1 pups (WT/ CS10, 11 heterozygous) were
successfully obtained from xy009 founders but not xy007. The reason could be that the
mutated allele frequency in xy007 was too low to get germline transmission. CS10, 11 KI
followed by an in-frame stop codon F1 pups (WT/ CS10, 11 TAG) were also derived. To
dilute out potential off-target effects from CRISPR-Cas9, derived heterozygous F1 CS10,
11
KI and CS10, 11 TAG were bred back to WT C57BL/6J mice for at least 3 generations.
One-time CS10, 11 KI F1 heterozygous crossbreed generated seven pups. Genomic DNAs
collected from neonatal tails were amplified and treated by Taq I enzyme digestion and
cleavage bands only in the presence of Taq I suggested homozygous KI pups
(Figure 3-14C). Homozygous mutations were further validated by Sanger sequencing
and compared to mouse Mcl-1 genomic sequences (Figure 3-14D).
Immunoblotting of neonatal tail fibroblast cells from the seven pups generated by
CS10, 11 KI F1 heterozygous mice showed no obvious lower band (Matrix isoform) of
MCL-1 in Taq I and Sanger sequencing validated CS10, 11 KI homozygous (#1 and #7).
Heterozygous (#2, #4, #5, and #6) exhibited decreased lower bands of MCL-1 compared
with WT littermate (#3) (Figure 3-15A). Subcellular localization suggested CS10, 11
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Figure 3-13. Deep sequencing shows mutations and mutation efficiencies in
founders after zygote injection
(A) DNA was extracted from the toe of each founder mouse generated from zygote
injection. Amplicons from different samples were pooled together and barcoded by
another round of PCR by using a Nextera Index Kit. The library prepared from the final
PCR products of indexed samples was subjected to a 300bp-paired-end sequencing with
Illumina Miseq for the targeted region. Red, green, and orange bars suggest deletion,
insertion, and replacement mutation, respectively. Percentages represent the mutated
allele frequencies.
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Figure 3-14. Derivation of CS10, 11 and 30 kD KI mice
(A) DNAs extracted from tails of KI F1 pups were amplified and subjected to Taq I
enzyme digestion. (B) DNAs extracted from tails of KI F1 pups were amplified and sent
for Sanger sequencing. (C) Genomic DNAs were extracted from the toes of the pups
derived from CS10, 11 KI F1 heterozygous crossbreeding. Then, DNA collected were
amplified and treated by Taq I enzyme digestion. (D) Amplicons collected were sent for
Sanger sequencing for further validation.
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Figure 3-15. Validation of CS10, 11 and 30 kD KI mice
(A) Western blot of the neonatal tail fibroblast cells from the WT, CS10, 11 KI
homozygous and CS10, 11 heterozygous validated from both Taq I and Sanger sequencing.
#1 and #7 are CS10, 11 KI homozygous, #2, #4, #5, and #6 are heterozygous, and #3 is WT
littermate. (B) Mitochondria enriched, heavy membrane (HM) or cytosol (S100) fractions
were isolated from CS10, 11 KI homozygous, heterozygous, and WT neonatal tail
fibroblast cells. Whole cell lysates (WCL) acted as a control. Fractions were resolved and
immunoblotted for MCL-1. OPA-1, BCL-2 or BAX worked as intermitochondrial
membrane, outer membrane or cytosolic marker, respectively. (C) Mitochondria isolated
from CS10, 11 KI homozygous, heterozygous, and WT neonatal tail fibroblast cells were
subjected to proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer
mitochondrial membrane (OMM), and detergent SDS was used to disrupt both inner and
outer mitochondrial membranes. Lysates were collected and subjected to immunoblot
analyses for MCL-1, OPA-1 (intermembrane marker), BCL-2 (outer membrane marker),
and ATP5B (matrix marker).
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MCL-1 enriched in the heavy membrane (HM) as WT MCL-1 (Figure 3-15B). Further
proteinase K assay indicated that WT MCL-1 retained dual localization as shown by
proteinase K sensitive upper band and resistant lower band (Figure 3-15C). CS10, 11 KI
MCL-1 only exhibited one band and was completely sensitive to enzyme digestion,
suggesting its outer mitochondrial only localization (Figure 3-15C).
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CHAPTER 4.

DISCUSSION

MCL-1 in Normal Biology
Gene-ablation study uncovered a non-redundant and distinct role of MCL-1 as a
BCL-2 family member. Deletion of Mcl-1 resulted in embryonic lethality due to periimplantation failure on E3.5 [16], however, genetic deletion of other anti-apoptotic BCL2 family members do not result in such severe phenotype [11-14]. Induced deletion of
Mcl-1 during different stages of hematopoiesis and different lineages indicates that MCL1 is essential for the survival and differentiation for multiple hematopoietic lineages,
including pre-B and progenitor T cells, HSCs, CMPs, CLPs, as well as mature
neutrophils, plasma cells, red blood cells, and NK cells, etc. [17-23]. In contrast, other
pro-survival family members play much more selective roles in hematopoiesis [11, 14,
24, 25]. Additionally, cardiac-specific ablation of Mcl-1 also leads to a dilated
cardiomyopathy and rapidly fatal phenotype [26, 27]. However, all previous gene
ablation studies disable both classical anti-apoptotic activity on the outer mitochondrial
membrane and mitochondrial function species in the mitochondria matrix. Therefore, to
determine the relative contribution of MCL-1’s different functional roles for supporting
the survival and differentiation of various cellular lineages, it is important to dissect the
two species. It is proposed that both species may be critical for normal cell biology,
including supporting survival, promoting proliferation and differentiation, as well as
regulating the homeostasis response to growth factors or cellular signals. However, these
two species may contribute differently during developmental stages or on distinct cell
types. For example, hematopoietic cells are highly proliferative and more vulnerable to
cellular stress, therefore, they are extremely dependent on anti-apoptotic MCL-1 for
survival. Another example are pluripotent stem cells which remain relatively metabolic
inactive by utilizing anaerobic glycolysis. When differentiating into their progenies,
metabolic demands from a major glycolysis to oxidative phosphorylation switch of those
pluripotent stem cells may require mitochondrial function of MCL-1.
MCL-1 in Embryonic Development
The study that germline ablation of Mcl-1 in mice resulted in an early periimplantation failure at E3.5 highlights a non-redundant and distinct role of MCL-1
among BCL-2 family members [16]. Other pro-survival members do not have such an
early developmental defect, suggesting that MCL-1 may have a unique function during
this early embryonic developmental stage. In the Mcl-1 germline ablation study, the
authors found deletion of Mcl-1 resulted in early embryonic lethality, however, they
claimed the defect was a trophectoderm (TE) defect rather than the inner cell mass (ICM)
apoptosis. This was demonstrated by the evidences that Mcl-1-null blastocysts failed to
attach in vitro and Mcl-1 null blastocysts show no signs of increased apoptosis, but a
delay in maturation beyond the pre-compaction stage, further indicating a role of MCL-1
beyond anti-apoptosis during early embryonic stage [16].
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In our study, we designed nine guide RNAs to target Mcl-1’s start codon and total
mutation efficiencies range from 75%-96%. Unlike SV40-transformed MEFs which can
tolerate MCL-1 loss, disruption of Mcl-1’s first methionine in ESCs all generated a 30 kD
short truncated protein of MCL-1 maintaining its anti-apoptotic core, suggesting that
MCL-1’s anti-apoptotic function is essential for ESC survival. Although 30 kD MCL-1
maintained classical anti-apoptotic function, mutant ESCs presented sick phenotypes and
failed to differentiate to extraembryonic endoderm, which is consistent with the
trophectoderm defect from genetic ablation of Mcl-1. Further q-PCR results even
suggested broad differentiation defects, including ectoderm, mesoderm, and endoderm
layers. Rescue experiment by putting back different MCL-1 mutant showed only WT
MCL-1 can fully rescue the differentiation defect of teratoma formation, neither antiapoptotic 30 kD, CS10, 11 MCL-1 nor mitochondria matrix species completely rescue the
defect. These data, taken together, suggest that in addition to MCL-1’s required
antagonism of cell death by the C-terminal region, MCL-1’s N-terminus is required for
efficient cellular differentiation, potentially by facilitating MCL-1’s import into the
mitochondrial matrix. However, the mechanistic underpinnings of the anti-apoptotic
function and mitochondrial promoting activity in determining ESC differentiation
remains to be elucidated.
Metabolic Requirements during Embryogenesis. Mitochondria of the oocyte
and early embryo are known to be small with few cristae and less electron transport
chains, but those mitochondria are highly active in oxidative phosphorylation to generate
ATP in support of the metabolic demands of early development [112-114]. And it is wellknown that mitochondrial replication of the oocyte is arrested in metaphase II of meiosis
and is only reactivated upon implantation into the uterine wall [115]. Post-fertilization,
mitochondria undergo dramatic maturation into the elongated “spaghetti-like” and
cristae-rich structures and failure to acquire this mature mitochondrial ultrastructure
results in arrested embryos [116-118]. Further following implantation, a transition from
glycolysis to oxidative phosphorylation is essential for successful early embryogenesis,
as shown by a developmental delay or late onset lethality with mutations that impair
oxidative metabolism [119, 120]. MCL-1 is required for early implantation, however the
mechanism has still remained elusive. It is possible that MCL-1 facilitates mitochondrial
ultrastructure and provides sufficient energy production that is required for the
trophectoderm to implant. Another possibility is that MCL-1 promotes mitochondrial
physiology and oxidative phosphorylation to prime the differentiation of cytotrophoblast
cells, failure of which results in a defective trophectoderm to implant. Therefore, it is
conceivable that other than MCL-1’s required antagonism of cell death, MCL-1’s role to
maintain normal mitochondrial physiology and promote differentiation is also important
during early embryonic development.
Metabolic Determinants of Embryonic Stem Cell Fate. Embryonic stem cells
are derived from the inner cell mass of the pre-implantation blastocyst around E3.5 and
represent the gold-standard of “stemness”, which means they obtain pluripotency,
capable of differentiating into broad tissue-specific lineages, and self-renewal, the ability
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to self-replicate maintaining the undifferentiated pool. Similar to their tissue origin,
embryonic stem cells are characterized by a low mtDNA content and immature
mitochondrial ultrastructure with poorly developed cristae, which is also a universal
feature across a variety of stem cell populations, including hematopoietic stem cells
(HSCs) and mesenchymal stem cells (MSCs) [121-123]. It is now well-accepted that
glycolysis fuels not only energy (ATP) but also building blocks (carbon, nitrogen, and
hydrogen) for stem cell proliferation and self-renewal [124, 125]. Stimulating glycolysis
in pluripotent stem cells through hypoxia or suppressing mitochondrial respiration
promotes “stemness” while inhibition of glycolysis halts proliferation and accelerates cell
death [126-128].
Pluripotent stem cells and their progenies have very different energetic
requirement. Differentiated cells no longer sustain high proliferation rate, but rather
perform specific specialized functions, such as rhythmic contraction in cardiomyocytes or
electrical impulses in neurons, therefore, they demand large amount of energy to fuel
those processes rather than anabolic synthesis for rapid proliferation [129]. When induced
to differentiate, specific energetic and metabolic capacities are required to overcome
barriers of the state conversion, evidenced by the downregulation of glycolysis and
stemness genes while stimulation of mtDNA replication, mitochondrial biogenesis,
maturation of extensive, interconnected networks of elongated and cristae-rich
mitochondria as well as upregulation of TCA cycle players and electron transport chain
components [123, 130-132]. Thus, a metabolic switch from glycolysis to mitochondrial
oxidative phosphorylation is essential for stem cell differentiation; however, the
mechanism of a causal role in cell fate determination remain to be unknown.
Several studies have emphasized that mitochondrial regulation of reactive oxygen
species (ROS) as well as stem cell differentiation inducers and antioxidants, impair the
differentiation capability of HSCs and MSCs [132-135]. Other researchers report that
several signaling pathways have been involved in regulating the metabolic switch. It is
well-recognized that Smad1 and STAT3 act as key components to support stemness of
pluripotent stem cells through signaling pathways mediated by bone morphogenetic
protein (BMP) and leukemia inhibitory factor (LIF), respectively [136, 137]. PI3KmTOR pathway has also been revealed by several studies to regulate stemness of HSCs
and tuberous sclerosis complex 1 (TSC1) activity, an upstream negative regulator of
mTOR, is required to support HSC stemness by repressing mitochondrial biogenesis and
ROS production [138-140]. Other than the metabolic regulation, cellular signaling,
epigenetic control of transcription programs has also been reported to determine the stem
cell fate. One example is that Moussaieff et al. showed that glycolysis-derived acetylCoA prevents histone deacetylation and blocks differentiation of ESCs [141].
In our work, we showed that N-terminal truncated mutant of MCL-1 ESCs failed
to differentiate to broad germ lineages, including extraembryonic endoderm, ectoderm,
mesoderm, and endoderm. N-terminal sequences of MCL-1 contain mitochondria
targeting sequences, deletion of which abrogates MCL-1’s importation into the
mitochondrial matrix. Matrix localized MCL-1 has been suggested to support
mitochondrial ultrastructure, promote mitochondrial fusion and fission, and facilitate the
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assembly of ATP synthase oligomers and oxidative phosphorylation [38]. It is possible
that in the absence of matrix species of MCL-1, ESCs cannot make the switch from
glycolysis to oxidative phosphorylation, and therefore, fail to overcome the energetic and
metabolic barriers to undergo differentiation. Another possibility is that the N-terminus of
MCL-1 is required for binding to certain key factors to activate differentiation pathways
or inhibit signaling that maintain pluripotency. It is suggested that MCL-1 interacts with
STAT3 at the window of implantation to promote the mesenchymal to epithelial
transition (MET) required for successful implantation [142, 143].
MCL-1 in Cardiac Homeostasis
Mitochondrial Function in Cardiomyocyte Development. The development of
the heart starts around E7.5, beating heart tube may be observed at E8.5, and the primary
four cardiac chambers are formed around E10.5 [144]. Cardiomyocyte development has
also been suggested to be dependent on mitochondrial status as cardiomyocytes from
early embryos around E9.5 which show sparse fragmented mitochondria with poorly
formed cristae and immature ultrastructure. Those immature mitochondria undergo
extensive maturation into elongated and branched mitochondria with abundant and
organized cristae by E13.5 [133]. Studies have shown that early induction of
mitochondrial maturation accelerates cardiomyocyte differentiation, while forced arrest
in the immature status of mitochondria impairs the differentiation of cardiomyocytes
[133, 145]. MCL-1 is essential for cardiac development as evidenced by our previous
study that induced deletion of Mcl-1 in heart by Ckmm-CRE at E13.5 leads to a fatal
dilated cardiomyopathy [26].
MCL-1’s Dual Functions in Heart Homeostasis. Cardiomyocytes are
permanent cells and they lose their regenerative ability after postnatal day 7; therefore,
they can only be repaired by connective tissues through fibrosis [146]. Deletion of Mcl-1
in adult mice heart by tamoxifen inducible Myh-CREER also results in a rapid, fatal
cardiomyopathy. However, low but significant levels of apoptosis was observed, which
is consistent with previous studies showing that even low levels of cell death are
sufficient to cause cardiomyopathy because they lack of regeneration capability [26,
147]. Further genetic ablation of pro-apoptotic Bax and Bak rescue the survival of
cardiac-specific Mcl-1 deletion and improves cardiac function, indicating that MCL-1
prevents heart failure and overt cardiomyopathy by blocking cell death [26]. Although
deletion of Bax and Bak rescues loss of Mcl-1 and those mice did not display significant
cardiac dysfunction, further analyses of the hearts from those mice reveal the
heterogeneous myocardial organization with rounded and disorganized mitochondria.
Respiratory defect as well as decreased mtDNA levels could not be rescued by Bax and
Bak deficiencies [26]. Additionally, cardiac-specific Mcl-1 deletion in the absence of
Bax and Bak shows cardiac dilation and contractile dysfunction under the isoproterenol
challenge [26]. Taken together, these data suggest that both anti-apoptotic species and
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mitochondria matrix species are necessary for heart homeostasis by promoting
cardiomyocytes survival and facilitating mitochondrial physiology, respectively.
MCL-1 in Hematopoiesis
Previous specific genetic ablation studies during different stages of hematopoiesis
revealed that MCL-1 is unique and required for development and maintenance of
hematopoiesis [17-23]. Deletion of MCL-1 in early hematopoietic progenitors, HSCs,
double-negative T cells and pro-B stages, leads to an increased apoptosis and arrested
development [17, 19]. In contrast, other pro-survival BCL-2 family members seem to
play much more selective roles limited to more mature cells. Genetic ablation of BCL-2
and BCL-XL leads to defects of mature lymphocytes and red blood cells, respectively [11,
24]. A1 isoforms play a role, but are not indispensable for granulocyte and lymphoid
development [14, 25]. Similar to embryonic stem cells discussed earlier, an energetic and
metabolic reprogramming from glycolysis to oxidative phosphorylation is a universal
feature across a variety of stem cell populations and is also essential for hematopoietic
lineage specification [121]. Therefore, it is possible that both the Matrix and antiapoptotic MCL-1 forms are required to provide metabolic demands for hematopoietic
lineage differentiation and to antagonize cell death to sustain maintenance of progenitor
pool, respectively.
More committed lineages, such as mature lymphocytes or myelocytes, have
different metabolic demands and no longer sustain high proliferation rate as their
progenitors, but rather perform immune surveillance or phagocytosis under the regulation
of cytokines and growth factors [6, 148]. Deletion of MCL-1 in mature hematopoietic
lineages, such as mature neutrophils, plasma cells, red blood cells, and NK cells, have
also been reported to cause dramatic increased apoptosis, indicating that more committed
lineages are highly regulated by apoptosis [18, 20-23]. It is conceivable that matrix
localized MCL-1 may be important for early progenitors as it facilitates the mitochondrial
physiology to prime stem cells for differentiation, while anti-apoptotic MCL-1 may be
more important for survival of the mature cells. Further studies are needed to separate
these two functions of MCL-1 in order to understand their individual contributions to
hematopoietic homeostasis.
MCL-1 in Cancer Biology and Cancer Therapy
MCL-1 has been reported to be overexpressed in many human cancers, including
acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic
lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), neuroblastoma,
melanoma, breast cancer, lung cancer [31]. The rationale for cancer cells displaying high
level of MCL-1 is that those cancer cells often violate important cellular checkpoints
which can drive the cells to die through apoptosis. Therefore, cancer cells need strategies
for survival under the increased apoptotic stress by either downregulating pro-apoptotic
regulators or, more frequently, upregulating pro-survival members like MCL-1 [36].
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More importantly, elevated level of MCL-1 expression often correlates with disease
progression, chemotherapeutic resistance and relapse, highlighting the importance of
understanding MCL-1’s contributions and regulations [32-35].
Targeting MCL-1 as an Anti-apoptotic Protein
Since cancer cells are so “addicted” to anti-apoptotic BCL-2 family members as
we discussed earlier, researchers have been working on developing small molecules to
antagonize those pro-survival members. ABT-737/263, navitoclax, binds specifically
with high affinity to pro-survival proteins BCL-2, BCL-xL, and BCL-w, but not to MCL1 and has been reported to induce regression of many solid tumors [94-96]. Though
ABT-737 shows promising killing effect in certain tumors, its efficacy as a single agent is
limited because of MCL-1 overexpression, which also represents a potential mechanism
of resistance [149, 150]. Furthermore, the dose-limiting severe thrombocytopenia from
navitoclax also quenched the enthusiasm for further clinical development of this
compound [151]. ABT-199, venetoclax, has been developed and shown to have subnanomolar affinity to BCL-2 with good anti-tumor activity sparing platelets on
preclinical studies of many leukemia and lymphomas [152-155]. Most recent clinical
trials have identified ABT-199 as a very effective drug either as a single agent or
combined with traditional chemotherapy drug on CLL, even in relapsed or refractory
patients, non-Hodgkin lymphoma, especially mantle cell lymphoma [156-158].
In 2016, Kotschy et al. developed a small molecule S63845 that specifically binds
to the BH3-binding groove of MCL-1 with high affinity and showed very potent antitumor activity with an acceptable safety margin either alone or in combination with other
traditional chemotherapy drugs in treating a variety of tumors, such as multiple
myelomas, leukemia, lymphoma cells and some other solid tumors [37]. The authors
showed that S63845 kills tumor cells in a pro-apoptotic BAX/BAK dependent manner,
which highlights MCL-1’s anti-apoptotic function as a target in cancer therapeutics [37].
This study provides preclinical evidence that MCL-1 is a promising target. Inhibition of
MCL-1 with S63845 is efficacious and tolerable, which may be explained by the
overexpression of MCL-1 in tumor cells, making them more vulnerable than normal
cells. Further studies are warranted to explore the potential of S63845 for the treatment of
human cancers.
Targeting Matrix-MCL-1 for Cancer Therapy
The function of MCL-1 in facilitating mitochondrial physiology offers another
clue for targeting MCL-1 in cancer therapeutics. In contrast to conventional opinions,
although mutations affecting mitochondrial functions are common in cancer cells, they do
not disrupt the energetic and metabolic functions but rather reprogram the mitochondrial
bioenergetics and biosynthetic status to meet the demands of cancer cells [43]. Functional
mitochondria are essential for cancer cell survival, and cancer therapies targeting
mitochondria have already been shown to be promising for cancer treatment [75].
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Over the past decade, it has been demonstrated that for various malignancies,
including leukemia and various solid tumors, cancer cells are heterogeneous and
functionally inequivalent. Studies have shown that despite identical genetic background,
there are a subset of cancer cells that acquire “stemness” features and have the ability to
self-renew and give rise to heterogeneous cancer population. Thus, such cancer cells have
been termed cancer stem cells (CSCs) or tumor-initiating cells (TICs) [159-161]. Similar
to the normal stem cells, CSCs have also been shown to adopt primarily aerobic
glycolysis over OXPHOS to maintain their “stemness” as well as proliferate [162-164].
The role of MCL-1 in facilitating mitochondrial physiology, especially promoting
OXPHOS, may be beneficial to promote cancer stem cell proliferation. Therefore, it is
possible that augmenting the function of matrix MCL-1 could be an effective strategy to
induce differentiation and deplete the cancer stem cell pool. Further studies are required
to separate the two functions of MCL-1 and find out their relative contribution to cancer
initiation and maintenance.
Potential Concerns of Targeting MCL-1 in Cancer Therapies
MCL-1 is essential for the survival and development of various cell types and
inhibition of MCL-1 results in massive cell death and tissue dysfunctions, as discussed
earlier [16-21, 26]. A previous study on S63854 provides preclinical evidence that MCL1 is a promising therapeutic target and its inhibition is efficacious and tolerable, which
may be explained by the MCL-1 dosage effect. Cancer cells are always displaying
increased copies of MCL-1 to avoid undergoing apoptosis, therefore, they are more
dependent on MCL-1 and more vulnerable than normal cells. However, for many cells
and tissues that are highly dependent on MCL-1 for survival and homeostasis, potential
adverse side effects will need to be monitored when targeting MCL-1.
Severe thrombocytopenia from ABT-263, navitoclax, is a good example that its
target BCL-XL is an essential pro-survival molecule for megakaryocyte survival to
produce platelets [151, 165, 166]. Importantly, our data demonstrate that the antiapoptotic character of MCL-1 is required to keep embryonic stem cells surviving. Both
anti-apoptotic and Matrix forms are essential for efficient cellular differentiation. Other
studies also suggest that MCL-1 is indispensable for cardiac homeostasis, hematopoiesis,
and other functions [17-21, 26]. Therefore, the potential adverse side effects associated
with pharmacological MCL-1 inhibition should be monitored, such as tissue
differentiation and regeneration defects, cardiotoxicity, as well as pancytopenia.
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CHAPTER 5.

FUTURE DIRECTIONS

Contributions of Both MCL-1 Species for ESCs Survival and Differentiation
Previous work from our laboratory has revealed that two forms of MCL-1 possess
different functions due to their distinct localization [38]. Outer mitochondrial membrane
localized MCL-1 performs the classical anti-apoptotic function by antagonizing BAX and
BAK. However, N-terminal proteinase processed matrix localized MCL-1 does not
possess anti-apoptotic activity, but plays a role in promoting mitochondrial physiology,
including maintaining mitochondrial ultrastructure, facilitating mitochondrial fusion and
fission, supporting the assembly of ATP synthase oligomers and oxidative
phosphorylation [38]. Our data show that N-terminal truncated 30 kD mutant ESCs,
although maintaining MCL-1’s anti-apoptotic function to help ESCs to survive, fail to
differentiate to broad germ lineages, indicating that function of MCL-1 beyond
antagonizing cell death is required for efficient cellular differentiation. Additionally,
rescue experiments by putting back different isoforms of MCL-1 showed that only WT
MCL-1 is capable of rescuing the differentiation defect of teratoma formation. Neither
anti-apoptotic only CS10, 11 MCL-1 nor mitochondria Matrix species can completely
rescue the differentiation defect, further suggesting both forms of MCL-1 are essential for
ESCs survival and differentiation.
Differentiation Rescue Experiments by Enforced Expression of MCL-1 Species
Our data demonstrate that only WT MCL-1 is capable of rescuing the
differentiation defect but neither OMM mutant anti-apoptotic CS10, 11 MCL-1 nor
mitochondria matrix species completely rescues the defect. Our future experiment will be
to enforce the expression of both forms of MCL-1 in Mcl-1-deficient ESCs to see if we
can get the complete rescue of differentiation. We could first transduce Mcl-1flox/flox
CREERT2 ESCs overexpressing MSCV-IRES-GFP 30 kD or CS10, 11 MCL-1 with MSCVI-mCherry Matrix MCL-1 and examine whether the 30 kD plus Matrix or CS10, 11 plus
Matrix MCL-1 ESCs are able to differentiate into multiple germ layers. To avoid multiple
rounds of transduction and flow sort, we could generate one construct with both 30 kD
and Matrix or CS10, 11 and Matrix connected by a 2A peptide [167].
Another strategy will be to first overexpress different MCL-1 mutants, 30 kD,
CS
or Matrix MCL-1, to the F12 ESCs and then performing the CRISPR-Cas9
targeting on the endogenous MCL-1. If both forms of MCL-1 are required for ESCs
differentiation, we expect to see that endogenous 30 kD mutant ESCs generated from
CRISPR-Cas9 overexpressing Vector, 30 kD or CS10, 11 MCL-1 will fail to differentiate
to any committed lineages. However, ESCs expressing the endogenous 30 kD mutant
transduced with either WT or Matrix MCL-1 should be able to undergo efficient
differentiation. By examining the design of our previous guide RNAs, crRNA-R1 could
be used to target the endogenous MCL-1 but sparing the exogenous MCL-1 mutants
because it targets the 5’-UTR of Mcl-1 genomic DNA.
10, 11

60

Determine Mechanistically How Both Forms of MCL-1 Regulate ESCs
Differentiation
Determine Physiological Mitochondrial Status of Mutant ESCs
Our work indicates both forms of MCL-1 are indispensable for efficient
differentiation of ESCs. However, future studies are needed to understand the
mechanisms by which OMM and Matrix MCL-1 collaborate to regulate cellular
differentiation. It is conceivable that OMM anti-apoptotic MCL-1 supports ESCs survival
by antagonizing BAX and BAK. This was suggested by our previous evidences that no
clone with complete Mcl-1 deletion survived after CRISPR-Cas9 targeting and Mcl-1deleted ESCs failed to expand in culture. Matrix MCL-1, however, may promote the
metabolic switch from aerobic glycolysis to OXPHOS by facilitating mitochondrial
physiology for ESCs to undergo differentiation.
Therefore, it is important to determine the physiological mitochondrial status of
WT ESCs comparing 30 kD mutant ESCs and Mcl-1flox/flox CREERT2 ESCs in the presence
or absence of tamoxifen. We could measure ATP production, oxygen consumption,
mitochondrial fusion and fission, supercomplexes of electron transport chain (ETC),
mtDNA and mitochondrial membrane potential. Previous work from our laboratory
suggests Matrix MCL-1 plays a role in maintaining mitochondrial ultrastructure,
facilitating mitochondrial fusion and fission, supporting the assembly of ATP synthase
oligomers and oxidative phosphorylation. Therefore, we expect to see that 30 kD mutant
ESCs or Mcl-1-deleted Mcl-1flox/flox CREERT2 ESCs, lacking Matrix MCL-1, have
defective mitochondrial respiration, decreased production of ATP and mtDNA, abnormal
mitochondrial ultrastructure as well as the disrupted electron transport chain
supercomplexes. Further experiment will be required to re-intrduce different mutants of
MCL-1 to see whether OMM anti-apoptotic MCL-1 or Matrix MCL-1 rescues the
mitochondrial physiology defects. We expect to see that WT MCL-1 or Matrix MCL-1
corrects the mitochondrial physiology defects of 30 kD mutant ESCs.
Determine Mechanistically How MCL-1 Regulates ESCs Differentiation
Our preliminary data suggested that when being induced by differentiation, fulllength MCL-1 protein expression was first increased peaking around 24 hours and then
decreasing around 30% at EB day 10 compared with ESCs at the starting point
(Figure 5-1A and B). The expression pattern of mRNA levels of Mcl-1 was consistent
with its protein expression, showing that Mcl-1 transcription was dramatically induced
for the first 24 hours of the differentiation process before the level dropped at the latter
time point (Figure 5-1C and D). Dab-2 mRNA level was performed as a positive control,
showing that the extraembryonic endoderm marker was induced along the differentiation
process (Figure 5-1E and F). These data suggest that MCL-1 may be an early response
gene under the regulation of either cytokines or signaling pathways during differentiation.
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Figure 5-1. MCL-1 expression is first induced and then decreased during
differentiation process
(A) Immunoblotting of F12 WT ESCs and embryoid bodies at different time point along
the differentiation for MCL-1, PARP, Caspase 3 and Actin. (B) Relative expression of
MCL-1 protein levels along the differentiation time course. (C) Real-time PCR of
induction fold change of control for Mcl-1 mRNA along the differentiation time course.
(D) The curve of relative expression of Mcl-1 mRNA levels during the differentiation
time course. (E) Real-time PCR of induction fold change of control for Dab2 mRNA
along the differentiation time course. (F) The curve of relative expression of Dab2
mRNA levels during the differentiation time course. The assay was done in triplicate for
each sample. Error bars represent the standard error of the mean.
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We further performed microarray analysis on Mcl-1flox/flox CREERT2 ESCs in the
presence or absence of tamoxifen. Principal components analysis (PCA) is a statistical
technique for demonstrating the key variables of multidimensional data set. It can be
used to simplify the analysis by visualization [168]. Our PCA and corrected PCA data
suggested that Mcl-1flox/flox CREERT2 ESCs control and Mcl-1-deleted ESCs were very
different across gene expression data sets (Figure 5-2A and B). Additionally, our gene
set enrichment analysis (GSEA) revealed many potential pathways involved.
Understandably, pathways being correlated with tumorigenesis, progression and invasion
have been identified because anti-apoptotic MCL-1 has been suggested to be involved in
cancer initiation, progression and relapse as we discussed earlier. Other than the possible
anti-apoptotic pathways, there are two top targets identified that may be relevant, SUZ12
and the epithelial to mesenchymal pathway (Figure 5-2C and D).
SUZ12 (suppressor of zeste 12), a Polycomb group (PcG) protein, together with
EZH2 (enhancer of zeste homolog 2) and EED (embryonic ectoderm development) form
the Polycomb repressive complex, PRC2 [169, 170]. SUZ12 is essential for PRC2
activity to repress transcription through methylation of lysine (K) 27 of histone (H3)
(H3K27 methylation). Inactivation of SUZ12 results in early lethality of mouse embryos
[171, 172]. It has been further shown that Suz12-/- ESCs failed to undergo proper
differentiation upon induction suggesting that SUZ12 is required for the repression of
genes essential for ESCs self-renewal, like Nanog and Oct4 [171]. Mcl-1-null ESCs
downregulated SUZ12, which is consistent with the differentiation defect phenotype
(Figure 5-2C). Future studies need to focus on how MCL-1 and SUZ12 are related to
facilitate ESCs differentiation. It is possible that SUZ12 is downstream of MCL-1,
thereby regulating the global methylation of H3K27. To test the hypothesis, SUZ12
overexpression experiment could be performed in Mcl-1-deleted or 30 kD mutant ESCs
to examine whether restoration of SUZ12 is capable of rescuing the differentiation defect.
If SUZ12 is the downstream effector of MCL-1, chromatin immunoprecipitation
sequencing (ChIP-Seq) and RNA sequencing (RNA-seq) could be initiated to understand
potential genes regulated by epigenetic control via the MCL-1-SUZ12 pathway.
Another pathway identified by GSEA was the upregulated epithelial to
mesenchymal transition (EMT) in Mcl-1-deleted ESCs (Figure 5-2D). Consistent with
our previous discussion, one study suggested that MCL-1 interacts with STAT3 at the
window of implantation to promote the mesenchymal to epithelial transition (MET),
essential for successful implantation [142, 143]. Therefore, it will be also important to
test how MCL-1 interacts with STAT3 to facilitate MET for ESCs differentiation and
embryo implantation. First, we could evaluate the expression level, subcellular
localization and phosphorylation status of STAT3 in the presence or absence of MCL-1.
If there is a difference, we could test whether restoration of STAT3 levels rescues the
differentiation defect. Furthermore, there are many STAT3 mutants (constitutively active,
dominant negative, or catalytic-dead mutant STAT3) that we could use to test how MCL1 and STAT3 interact with each other.
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Figure 5-2. Potential changes of signaling pathways are identified in Mcl-1deleted ESCs
(A) Principal components analysis and (B) corrected PCA data comparing Mcl-1flox/flox
CREERT2 ESCs control and Mcl-1-deleted ESCs. (C) Top 1st and (D) top 4th hits of
possible downregulated and upregulated signaling pathways from GSEA by comparing
Mcl-1-deleted ESCs versus Mcl-1flox/flox CREERT2 ESCs control. Mcl-1flox/flox CREERT2
ESCs treated with 48 hours tamoxifen were statistically tested by unequal variance t test
to the DMSO control (3 replicates). P values for both downregulated SUZ12 and
upregulated EMT pathways are 0.000.
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Determine the Phenotypes of CS10, 11 and 30 kD MCL-1 KI Mice
Our work showed that CS10, 11 and 30 kD MCL-1 KI heterozygous were
successfully derived. Because of potential off-target effects from CRISPR-Cas9
targeting, our F1 heterozygous mice were backcrossed to WT C57BL/6 mice [173]. After
backcrossing, they will be crossbred and the Mendelian ratio will be calculated. Future
experiments will set out to try to figure out the phenotypes of CS10, 11 and 30 kD MCL-1
KI Mice. To determine whether CS10, 11 and 30 kD MCL-1 KI ESCs have defects in
differentiation, ESCs from KI homozygous mice will be derived and differentiation
assays will be repeated. It will be also interesting to check whether there are any defects
in hematopoiesis, cardiac homeostasis, and malignant transformation, where both forms
of MCL-1 seem to play important roles.
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